Synthesis and stability evaluation of novel peptidomimetic Caspase-1 inhibitors for topical application

Sandrine Chambon^a, Sandrine Talano^a, Corinne Millois^a, Laurence Dumais^a, Romain Pierre^a, Loïc Tomas^a, Céline Mathieu^a, Anne-Laurence Ghilini^a, Nicolas Vanthuyne^b, Kevin Reverse^a, Anne Brethon^c, Vincent Rodeschini^c, Catherine Comino^a, Grégoire Mouis^a, Ghizlane El-Bazbouz^a, Laurence Clary^a, Jean-François Fournier^a, Claire Bouix-Peter^a, Craig S. Harris^{a,*}, Laurent F. Hennequin^a

^a Nestlé Skin Health R&D, 2400 Route de Colles, 06410 Biot, France

^b Aix-Marseille Univ., CNRS, Centrale Marseille, iSm2, Marseille, France

^c Edelris, 115 Avenue Lacassagne, 69003 Lyon, France

A B S T R A C T

During our search for topically-active Caspase-1 inhibitors, we identified a novel class of potent inhibitors based on a 1,3,5-trisubstituted uracil motif equipped with an L-aspartate semi-aldehyde derived warhead. In the literature, the majority of Caspase-1 inhibitors possessing the same warhead have been designed and evaluated for oral administration as the ethyl acetal pro-drug form. For our topical program, the pro-drug acetal form was not fully hydrolysed in the skin and was unstable in many of our standard topical excipients, therefore, we were obliged to focus on the actual hemiacetal drug form of the molecule during our drug discovery program. Our work focuses on both the synthesis and achiral and chiral stability of the final drug molecules in topical excipients.

1. Introduction

Caspases are a family of protease enzymes called Cysteine Aspartic Proteinases. There are 12 known Caspases in humans. Caspases 1, 4, 5, 11 and 12 are all inflammatory caspases and 2, 3, 6, 7, 8, 9 and 10 are all associated with apoptosis [1]. All caspase substrates are cleaved from the C-terminus of an aspartic acid residue C-terminal in the P1 region of the binding site. Interleukin-1 β converting enzyme (ICE), also known as Caspase-1, is the principal enzyme responsible for cleavage and activation of pro-Interleukin-1 β (pro-IL-1 β) to its active form IL-1 β , which in turn is involved in the pathogenesis of several inflammatory disorders including acne vulgaris [2]. The cleavage of pro-IL-1 β to IL-1 β occurs through deprotonation of a cysteine residue via a neighbouring histidine. Cytokine IL-1 β plays an important role in local and

systemic inflammation and has been reported to target numerous cells involved in inflammatory acne [3]. In a recent study, we reported a comparison of lesional versus non-lesional biopsies of patients with inflammatory acne and through transcriptomic and proteomic studies, we showed a strong induction of IL-1 β mRNA and IL-1 β protein in lesional biopsies [4]. Consequently, the treatment of inflammatory acne with a topical agent targeting Caspase-1 presented an exciting and novel opportunity for the treatment of moderate to severe acne.

Medicinal chemists have developed potent inhibitors of the catalytic site principally by using masked aldehydes [5]. These form a reversible covalent linkage with the cysteine residue to block the enzyme from functioning. In 1992, Thornberry et al., inspired from the actual sequence of Caspase 1 substrate pro-IL-1 β , discovered a tetrapeptide motif, Ac-YVAD-CHO with nanomolar potency against Caspase 1. The C-terminus of the aspartic acid residue was modified to an aldehyde resulting in reversible covalent inhibition of the enzyme through a hemithioacetal linkage (Fig. 1).

* Corresponding author.

E-mail address: craig.harris@galderma.com (C.S. Harris).

Fig. 1. Binding mode of Ac-YVAD-CHO in Caspase 1 (Black, P4 pocket; blue P3/P2 region; red, P1 warhead region).

To overcome the poor ADMET of the early peptidic leads, potent peptidomimetic inhibitors of Caspase-1 [6], Pralnacasan (VX740) and Belnacasan (VX765) were developed and have been progressed to clinical studies for the treatment of rheumatoid arthritis and treatment-resistant epilepsy. Inspired by their approach, we set about designing our own cyclic peptidomimetic inhibitors based on scaffolds while preserving the 3 point H-bonding network and the aspartaldehyde warhead (Fig. 2) [7].

2. Results and discussion

We developed several synthetic strategies to deliver the piperidin-2,6-dione and pyrrolidin-2,5-dione based inhibitors that we have already detailed in a recent communication [8], focusing principally on: a) P1 warhead exploration; and b) probing the P4 region both exemplified in Schemes 1 and 2, respectively.

For topical medicinal chemistry, activity is always an important driver but the solution stability of our actives is another major consideration as the API is not formulated in solid form but in wet form such as creams, lotions or gels [9]. The topical excipient selected for screening purposes was a 96% w/w aqueous ethanol. Solutions at 0.01% (w/w) were monitored by HPLC during 3 months. Ideally, we would expect our developable candidate to have >90% of its original peak area remaining after 3 months at 40 °C. This can be extrapolated to a shelf-life over >1yr in the final topical formulation at room temperature [10].

Early on in our investigations, we established that the ethyl acetal pro-drug form (eg., **8**) of our final compounds was actually less stable than the hemiacetal drug form (eg., **1** and **2**) in all of our topical excipients. Moreover, the pro-drug was also not cleaved sufficiently quickly enough to the drug form in our in vitro and

Fig. 2. Our design rationale for a new classes of imide-based peptidomimetic Caspase-1 inhibitors.

Scheme 1. A representative route designed for P1 exploration and used to deliver eg., **1**. Reagents and conditions: (a) EDCl, DCM, 16 h, r.t.; (b) H-Ala-OtBu.HCl, DIPEA, 2 h, r.t.; (c) EDCl, HOBT (1.5 eq.), 16 h, r.t., 58%; (d) 4 M HCl in dioxane, EtOAc, 5 °C, 16 h, quant.; (e) 2-naphthoyl chloride, DIPEA, THF, 0 °C-r.t., 4 h, 59%; (f) TFA-DCM (1:3), r.t., 6 h, quant.; (g) Pd(PPh₃)₄, DMBA, DCM, r.t., 15 min; (h) **5** pre-activated EDCl, HOBT, DCM, DMF, 0 °C, 15 min, amine from step (g) added, r.t., 16 h, 72%; (i) TFA, DCM, r.t., 59%; (j) 2N HCl (aq), MeCN, 0 °C-r.t., 32%.

Scheme 2. A representative route designed for P4 exploration and used to deliver eg., **2**. Reagents and conditions: (a) K₂CO₃, MeCN, r.t., 53%; (b) TFA, 0 °C-r.t., quant.; (c) Pd(PPh₃)₄, DMBA, DCM, r.t., 15 min; (d) **10** pre-activated EDCl, HOBT, DCM, DMF, 0 °C, 15 min, amine from step (c) added, r.t., 16 h, 62%; (e) H₂, Pd(OH)₂-C, EtOAc, r.t., 78%; (f) TEA, DCM or 43%; (g) TFA, DCM, r.t., 75%; (h) 2N HCl (aq), MeCN, 0 °C-r.t., 52%.

in vivo assays. Therefore, we targeted the preparation of the drug form of our final compounds for evaluation in our testing cascade.

Both pyrrolidin-2,5-dione and piperidin-2,6-dione scaffolds **1** and **2** provided our first lead compounds with moderate activity 2400 nM and 1500 nM, respectively, against Caspase-1 (Schemes 1 and 2). However, the stability studies were very disappointing with all of our early designs. Both drug (**1**, **2**) and pro-drug (**8**) did not achieve an acceptable level of stability (>90%) at 40 °C after just 30 d and only **2** had acceptable stability with just 9% degradation at 23 °C after 30 days (Fig. 2). It is also interesting to note that the drug form **1** was more stable at 40 °C than the pro-drug form **8** with 70% versus 58% of the original peak remaining, respectively (Fig. 3).

By HRMS, we managed to identify the principal degradation products of our lead piperidin-2,6-dione series being due to ring-opening and loss of the warhead, not through hydrolysis of the amide bond but through tautomerisation followed by alcoholysis of

Fig. 3. Comparative stability evaluation of **1**, **2** and **8**.

the intermediate enamine or by a retro-Michael reaction (Fig. 4).

To overcome this stability issue of the piperidin-2,6-dione series, we decided to transpose our SAR to a 1,3,5-trisubstituted uracil scaffold [7,11]. We anticipated that the stability issues would be addressed by preventing ring opening and replacing the sensitive chiral center at C3-H of the piperidin-2,6-dione unit that we had great difficulty in controlling during the assembly of our final products (eg., **1** and **14**) [8]. The first match pair (**14** v **15**), incorporating Sunesis' quinoxaline P4 fragment [12], showed an impressive ~40 fold gain in potency and solution stability improved significantly, 55% v 84%, respectively. However, during the assembly of our final molecules we encountered great difficulty to control the stereogenic center off N-3, finishing routinely with a racemate. To overcome this epimerization issue, we introduced a cyclopropyl group [13]. Indeed, as discussed previously by us [7], we suspected that it should be accommodated in the limited space in the binding cleft between Val³³⁸ and Trp³⁴⁰. Moreover, after further SAR (structure activity relationship) and SPR (structure property relationship) investigation, we identified **16** as our new lead candidate with much improved potency, stability, photosafety and synthetic feasibility (Fig. 5) [7].

The key step for our uracil fragments relied on a novel 3 MCR (multi-component reaction) construction of the 5-nitrouracil fragment (**21**) with a cyclopropyl moiety at N-1 described in a recent letter [13]. From **21**, alkylation at N-3 followed by reduction using dissolving metal conditions [14] afforded the amino P2/P3 fragment **23**, coupling with the optimized P4 fragment (**24**) using COMU ((1-cyano-2-ethoxy-2-oxoethylideneaminoxy)dimethylamino-morpholino-carbenium hexafluorophosphate) [15], followed by Alloc deprotection afforded **25**. The synthesis terminated with installation of the precyclised P1 warhead fragment **26**

Fig. 4. Major product distribution of **2** determined by LC-HRMS in 96% w/w EtOH(aq) after heating at 40 °C for 30 days.

Fig. 5. A simplified SAR and SPR evolution of the early lead based on a piperidin-2,6-dione P2/P3 peptidomimetic scaffold to the optimized 1,3,5-trisubstituted uracil scaffold.

through a one-pot Alloc deprotection/amide coupling step followed by hydrolysis of the pro-drug ethyl acetal **27** to afford hemiacetal **16** (Scheme 3).

Our new lead compound **16** was not only more than 150 times more potent but also much more stable than our early designs **1** and **2** (Fig. 6) [7]. After 30 d at 40 °C, only 17% degradation was observed with compared to 50% with our first lead **1**. Although we had not achieved <10% degradation after 3 months at 40 °C, we were confident that we could achieve our target value by exploring other topical excipients. As illustrated previously (Fig. 3), the pro-drug form (**27**) was also less stable than the drug form (**16**) with 60% versus 40% degradation observed after 3 months at 40 °C, respectively.

As we moved further into lead optimisation, we prepared the enantiomer (**28**) of our lead compound (**16**) to test its activity and use as a standards to monitor potential chiral degradation (epimerization at C-3) of the P1 warhead fragment. Although the furanone warhead of compound **16** has two chiral centers, the C-2-OH epimers are rapidly interconverting through ring opening and closing of **16**-aldehyde. Consequently, at best, immediately after

Scheme 3. Principal route employed for the preparation **16** and its analogues. Reagents and conditions: (a) KOCN, water, reflux, yield 78%; (b) Allyl bromide, DIPEA, THF/H₂O (10:1), 60 °C, 18 h, yield 68%; (c) ethyl nitroacetate, triethyl orthoformate, toluene, reflux, yield 79%; (d) Cs₂CO₃, MeCN, reflux, 78%; (e) 2-iodopropane, K₂CO₃, DMF, r.t., 24 h, 46%; (f) Fe(s), NH₄Cl(aq), THF, EtOH-H₂O, 70 °C, 1 h, 98%; (g) **24**, COMU, NMM, DMF, 50 °C, 48 h, 90%; (h) Pd(PPh₃)₄, DMBA, DCM, r.t., 45 min, 60%; (i) i. deprotection of **26**, Pd(PPh₃)₄, DMBA, DCM, r.t., 15 min; ii. pre-activation of **25** with HATU, DIPEA, DCM-DMF, r.t., 16 h; iii. products from step i added dropwise to ii and reaction mixture stirred at r.t., 16 h, quantitative; (j) 2M HCl (aq), MeCN, r.t., 2 h, 65%.

Fig. 6. Comparative stability evaluation of **16** versus its prodrug **25** and early piperidin-2,6-dione lead **2**.

the hydrolysis of the pro-drug, we obtain **16** as a 1:1 mixture of diastereomers (3*S*, 2*RS*), racemic at the hydroxyl-bearing carbon C-2 (Scheme 4).

Both **16** and **28** were prepared separately and assayed. They were equipotent which was surprising looking at what had been reported in the literature, raising the question of whether epimerization at C-3 was occurring during hydrolysis of the pro-drug or during storage in DMSO solution. We confirmed that epimerization was not occurring at the hydrolysis stage either by reduction of the aldehyde **16** to the alcohol **29** or by condensation to the benzylloxime **30** immediately after isolation. Therefore, epimerization must be occurring during dissolution and storage of **16** in DMSO or during the in vitro assay (Scheme 5).

Next, we decided to study the chiral stability of **16** in our model excipient (96% EtOH (aq)). While we could have employed the derivatisation methods shown in Fig. 7 to monitor chiral degradation at selected time points, we wanted to eliminate all possible contributory factors and focused on the development of a chiral chromatographic method.

The separation of racemic **16** was tested by a preliminary screening of 8 chiral columns (Chiralpak IA, IB, IC, ID, IE, IF, Whelk-O1 and Ulmo) with a mixture heptane/ethanol/chloroform (2/4/4) as the mobile phase. Chiralpak IC, cellulose tris(3,5-dichlorophenylcarbamate) polymer immobilized on silica, proved to be able to partially separate the enantiomers as shown on the reported UV chromatogram (Fig. 7a). The analytical conditions on this column were then optimized. The use of less polar eluent gave broad peaks (Fig. 7b), heptane/ethanol binary mixtures improved the enantioselectivity but with fronting of the 2 peaks (Fig. 7c), separation was lost with heptane/2-propanol mixtures and enantioselectivity decreased rapidly as temperature was increased. Finally, addition of 0.5% of triethylamine in the mobile phase allowed a baseline separation of the enantiomers with an enantioselectivity of 1.9 and a resolution of 1.8 (Fig. 7e). We retained these conditions to follow the chiral degradation of our final products.

The appearance of an additional peak in the presence of TFA (Fig. 7d) was interesting and prompted us to invest more time in

Fig. 7. Chiral HPLC method development for the separation of the enantiomer of **16**: Chiralpak IC, 1 mL/min, 25 °C, detection UV at 330 nm.

method development. We hypothesized that under this condition, the extra peak arose from the start of the separation of the diastereomeric warheads (*ie.*, in the case of **16**, 3*S*/2*S* from 3*S*/2*R*). Further screening of different columns and a new optimisation of the analytical conditions highlighted an exchange between different species, as indicated by the shape of the chromatograms (Fig. 8). In this acidic condition, at 40 °C, the opened aldehyde forms are in equilibrium with the hydroxy-furanone ring forms and all 4 diastereomers could be distinguished along with later running peaks that we assumed to be the open aldehyde forms assigned on the basis of mass spectrometry alone. These observations confirmed the configurational stability of the carbon bearing the nitrogen atom and the fast epimerization of the carbon bearing the hydroxyl group.

With our optimized chiral chromatographic conditions in hand (Fig. 7e), we monitored the chiral degradation of **16** in different excipients. Routinely, in the lead optimisation phase of our drug discovery programs, we would be expecting to achieve an e.r. of

Scheme 4. Proposed mechanism of epimerization of **16**.

Scheme 5. Methods developed to test for epimerization during hydrolysis step.

Fig. 8. Equilibria between opened and closed warhead forms of **16** & **28** evidenced by chromatographic profile on Chiralpak IA, 1 mL/min, 40 °C, detection UV at 330 nm.

≥95:5. As attested by the results in Table 1, racemisation was practically complete at 40 °C after just 1 d in 96% v/v EtOH (aq). Even after 30 d of storage at 0 °C, an unacceptable e.r. of 89/11 was obtained (entry 1). Similar results were also obtained as a 0.1% w/w solution in other commonly employed topical excipients from our screening panel. In summary, with **16** in solution, we were unable to significantly alter the rate of chiral degradation despite screening a wide variety of topically-acceptable solvents under various conditions (temperature, concentration, pH) [16]. Therefore, we switched to a suspension formulation by micronizing **16** and suspending the micronized solid in different media as a 1% w/v suspension (entries 2 and 3). While there was little improvement in chiral and achiral degradation in water compared to 96% EtOH (aq) (entry 2 v entry 1), only minor degradation was observed in oil at 23 °C after 3 months (entry 3) (Table 1).

With these results in hand we switched our focus back on chemical modifications to prevent chiral degradation altogether. The synthetic routes for the novel six-membered warheads **37–39** were very similar to those employed for the preparation of our aspartaldehyde warhead **6** (Table 1) [17]. However, we were unable to transpose the same methodology for the preparation of the quaternary warhead **35** and had to change our strategy. Briefly, Fmoc protection of commercially-available (*S*)-2-amino-4-(*tert*-butoxy)-2-methyl-4-oxobutanoic acid (**31**) followed by reduction of the carboxylic acid **32** to the alcohol through reduction of the mixed anhydride using NaBH₄. Fmoc deprotection afforded amine **33** followed by amide coupling with **34** using HATU afforded **35**. Finally, oxidation of the alcohol using Dess-Martin periodinane (DMP) to the aldehyde followed by deprotection of the *tert*-butyl protecting group using TFA afforded **36** albeit in poor yield (Scheme 6).

Evaluation of the P1 warheads is shown in Table 2. The non-epimerisable quaternary warhead **36** (entry 3) was inactive despite encouraging docking studies. It is interesting to note that there is 18 fold loss of activity by switching the configuration from *R* (**37**) to *S* (**38**) for the 6-membered non-epimerisable warhead match pairs (entries 4 and 5). While the *R* warhead **37** was moderately potent at 130 nM, it was unfortunately much less stable than **16** with only 64% of the compound remaining after 30 d at 40 °C. As the activity of our both 5-membered warhead enantiomers (**16** and **36**) was identical, we can safely assume that epimerization must be happening readily during our assaying of **16** in the enzymatic screen (entries 1 v 2). Finally, the direct 6-membered cyclic analogue of our lead warhead (**39**) was only moderately active at 560 nM.

3. Conclusion

In conclusion, we have described the synthesis and stability evaluation of a novel class of potent peptidomimetic Caspase-1 inhibitors based around cyclic imidic central cores with the hemiacetal drug-form of the warhead. Our SAR and SPR exploration

Scheme 6. Route employed for the preparation **36**. Reagents and conditions: (a) Fmoc-OSuc, 10% Na₂CO₃ (aq), dioxane, r.t., 12 h, 85%; (b) IBCF, NMM, DME, 0 °C, 1 h then add NaBH₄, rt, 18 h, 98%; (c) Pyrrolidine-MeCN (10% v/v), r.t., 16 h, quant.; (d) HATU, NMM, DMF, 80 °C, 4 h, 45%; (e) Dess-Martin periodinane, DCM, 0 °C to r.t., 2 h, quant.; (f) 2. TFA, DCM, rt, 1 h, 35%.

Table 2
Comparison of the hemiacetal P1 Warheads.

Entry	Compound	Warhead	IC ₅₀ (nM)	Stability ^b
1	16		10	84
2	28		10	88
3 ^a	36		5900	79
4	37		130	64
5	38		2400	68
6 ^a	39		560	85

^a Not a direct match pair.

^b Compounds were tested as 1% w/w solutions in 96% w/w EtOH (aq) at 40 °C for 30 d.

Table 1
Chiral and achiral integrity study of **16** in different excipients.

Entry	Excipient	Conditions	Chiral stability (3 <i>S</i> ,2 <i>RS</i> /3 <i>R</i> ,2 <i>RS</i>)	Achiral stability
1	0.01% w/w in 96% EtOH (aq) ^a	0 °C 23 °C 40 °C	89/11 after 30 d 83/17 after 1 d 55/45 after 1 d	N/A >95%/6 mo. 84%/30 d
2	1% w/w ^b in water	0 °C 23 °C 40 °C	>99/1 after 30 d 88/12 after 1 d 55/45 after 1 d	N/A 83%/1 mo. N/A
3	1% w/w ^b in oil Primol 352	0 °C 23 °C 40 °C	N/A 95/5 after 3 mo. 92/8 after 1 mo.	N/A >95%/6 mo. N/A

^a Similar results were obtained in other common topical excipient medium including H₂O, 2-propanol, propylene glycol, schercemol.

^b **16** was micronized and suspended in the medium; N/A = not assayed.

drove us to identify a uracil-based P2/P3 peptidomimetic scaffold showing excellent potency and much improved achiral stability in solution in our standard excipients. The chiral and achiral stability of the hemiacetal warhead series proved to be the most challenging aspect of our exploration. This was studied in solution and was, to some extent, controlled through micronisation of the API and suspension in an oil medium.

4. Experimental

¹H NMR spectra were recorded on a Bruker Biospin Avance 400 spectrometer unless otherwise stated. Chemical shifts are reported as δ values downfield from internal TMS in appropriate organic solutions. The abbreviations used for explaining the multiplicities were as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. For compounds isolated as mixtures of isomers, the ¹H integration is described as fractional integration according to the ratio of isomers. High resolution mass (ESI HRMS) was recorded on a Thermofisher Q Exactive™ Hybrid Quadrupole-Orbitrap™ Mass Spectrometer. The relative purity and the mass of the products were confirmed by LC/MS (220 nm–420 nm) on a Waters acquity uplc photodiode array detector system using the following conditions: Column, BEH C18 50*2.1 mm; 1.8 μ m; Solvent A, water 0.1% formic acid or water ammonium carbonate 2 g/L; Solvent B, CH₃CN; flow rate, 0.8 mL/min; run time, 2.2 min; gradient, from 5 to 95% solvent B; mass detector, Waters SQ detector. All compounds were purified by LC/MS on a waters Auto-purification system using the following conditions: Column, Xbridge C18 150*30 mm, 5 μ m; Solvent A, water 0.1% formic acid or water ammonium carbonate 2 g/L; Solvent B, CH₃CN; flow rate, 50 mL/min; run time, 10 or 15 min; with adapted isocratic elution mode; mass detector, Waters ZQ detector.

4.1. *N*-((3*R*)-1-((2*S*)-1-(((3*S*)-2-hydroxy-5-oxotetrahydrofuran-3-yl)amino)-1-oxopropan-2-yl)-2,5-dioxopyrrolidin-3-yl)-2-naphthamide (1) was prepared in 7 steps

4.1.1. *tert*-Butyl (S)-2-((*R*)-3-((*tert*-butoxycarbonyl)amino)-2,5-dioxopyrrolidin-1-yl)propanoate (4)

To a suspension of Boc-D-Asp-OH (**3**, 2.0 g, 8.58 mmol) in DCM (60 mL) at 0 °C was added EDCI (1.98 g, 10.2 mmol). The reaction mixture was stirred at room temperature for 1 h, cooled at 0 °C then L-Ala-OtBu.HCl (1.48 g, 8.15 mmol) and DIPEA (3.0 mL, 17.1 mmol) were added successively. The reaction mixture was stirred at room temperature for 1 h 30 min, cooled to 0 °C then EDCI (1.98 g, 10.2 mmol) and HOBt (1.28 g, 9.43 mmol) were added. The reaction mixture was stirred at room temperature for 16 h 1N HCl (aq) was added and the mixture extracted using DCM. The organics were washed sequentially with a saturated solution of NaHCO₃ (aq), 1N HCl (aq), brine, dried over Na₂SO₄, filtered and concentrated under vacuum. The residue was purified by silica gel flash chromatography (cyclohexane/EtOAc, gradient of 1/0 to 1/1) to give expected product (1.72 g, 58%) as a white solid: LCMS ESI⁺ *m/z* 343 (M+H)⁺, 360 (M+NH₄)⁺; ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.55 (d, *J* = 8.0 Hz, 1H), 4.62 (q, *J* = 7.2 Hz, 1H), 4.38–4.30 (m, 1H), 2.97 (dd, *J* = 17.5, 9.5 Hz, 1H), 2.60 (dd, *J* = 17.5, 6.0 Hz, 1H), 1.38 (s, 9H), 1.37 (s, 9H), 1.30 (d, *J* = 7.0 Hz, 3H).

4.1.2. *tert*-Butyl (S)-2-((*R*)-3-amino-2,5-dioxopyrrolidin-1-yl)propanoate hydrochloride

To a solution of *tert*-butyl (S)-2-((*R*)-3-((*tert*-butoxy-carbonyl)amino)-2,5-dioxopyrrolidin-1-yl)propanoate (1.0 g, 2.92 mmol) in EtOAc (20 mL) at 0 °C was added HCl (4N in dioxane, 7.3 mL, 29.2 mmol, 10 eq.). The solution was stirred at room temperature for 5 h then at 4 °C during 15 h. The solvent and excess HCl were

removed under reduced pressure at room temperature. The residue was taken-up in EtOAc and the solvent evaporated again to give expected product (850 mg) as beige solid. The product was engaged directly in the following step without further purification: LCMS ESI⁺ *m/z* 243 (M+H)⁺.

4.1.3. *tert*-Butyl (S)-2-((*R*)-3-(2-naphthamido)-2,5-dioxopyrrolidin-1-yl)propanoate

To a solution of *tert*-butyl (S)-2-((*R*)-3-amino-2,5-dioxopyrrolidin-1-yl)propanoate hydrochloride (810 mg, 2.91 mmol) in THF (20 mL) at 0 °C was added 2-naphthoyl chloride (665 mg, 3.48 mmol) followed with DIPEA (1.78 mL, 10.2 mmol). The reaction mixture was stirred at room temperature for 4 h then hydrolysed with H₂O and extracted with EtOAc. The organic phase was washed with aq. 1N HCl and brine, dried over Na₂SO₄, filtered and concentrated under vacuum. The residue was purified by silica gel flash chromatography (cyclohexane/EtOAc, gradient of 1/0 to 3/7) to give expected product (800 mg, 59%) as a beige solid: LCMS (*t*_R = 3.53 min, purity = 96%) ESI⁺ *m/z* 397 (M+H)⁺, 414 (M+NH₄)⁺; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.38 (d, *J* = 7.5 Hz, 1H), 8.47 (s, 1H), 8.06–7.96 (m, 3H), 7.92 (dd, *J* = 8.5, 2.0 Hz, 1H), 7.68–7.58 (m, 2H), 4.76 (m, 1H), 4.69 (q, *J* = 7.0 Hz, 1H), 3.12 (dd, *J* = 17.5, 9.2, Hz, 1H), 2.81 (dd, *J* = 17.5, 5.2 Hz, 1H), 1.41 (s, 9H), 1.39 (t, *J* = 7.0 Hz, 3H); Chiral HPLC (Chiralpak AD, *n*-heptane/2-propanol (80/20), 1 mL/min., *t*_R = 19.46 min, purity = 100%).

4.1.4. (S)-2-((*R*)-3-(2-Naphthamido)-2,5-dioxopyrrolidin-1-yl)propanoic acid (5)

To a solution of *tert*-butyl (S)-2-((*R*)-3-(2-naphthamido)-2,5-dioxopyrrolidin-1-yl)propanoate (800 mg, 2.02 mmol) in DCM (5 mL) at 0 °C was added TFA (1.55 mL, 20.2 mmol). The solution was stirred at room temperature for 6 h. Then the solvent and excess TFA were concentrated under vacuum. The residue was co-evaporated with DCM, then with EtOAc, and dried under vacuum. Expected product was isolated as a beige solid (690 mg, quant.) and was used without further purification.

4.1.5. *tert*-Butyl (S)-3-(((allyloxy)carbonyl)amino)-4,4-diethoxybutanoate (6) was prepared in 4 steps

Step 1: To a cooled (4 °C) solution of L-aspartic acid 4-*tert*-butyl ester (25.0 g, 132.1 mmol) in THF/H₂O (80 mL/240 mL) were added sodium bicarbonate (44.4 g, 528.5 mmol) and allyl chloroformate (25.3 mL, 237.8 mmol). After 2h30 of stirring at room temperature, the medium was extracted with EtOAc (three times). The aqueous layer was acidified with aqueous HCl (6 N) until obtaining pH 2. The aqueous layer was extracted (EtOAc, three times). The combined organic layer was dried over sodium sulphate, filtered and concentrated in vacuo to afford (S)-2-(((allyloxy)-carbonyl)amino)-4-(*tert*-butoxy)-4-oxobutanoic acid (29.2 g, 80%) as a pale yellow oil: LCMS ESI[−] *m/z* 272.4 (M-H)[−]; ¹H NMR (CDCl₃, 500 MHz) δ 5.87–5.96 (m, 1H), 5.74 (bd, *J* = 8.5 Hz, 1H), 5.31 (m, 1H), 5.22 (m, 1H), 4.55–4.65 (m, 3H), 2.97 (dd, *J* = 17.0 Hz and 4.0 Hz, 1H), 2.76 (dd, *J* = 17.0 Hz and 5.0 Hz, 1H), 1.44 (s, 9H).

Step 2: To a cooled (4 °C) solution of (S)-2-(((allyloxy)carbonyl)amino)-4-(*tert*-butoxy)-4-oxobutanoic acid (29.1 g, 106.4 mmol) in DCM (600 mL) were added N,O-dimethylhydroxylamine hydrochloride (12.4 g, 127.8 mmol), 4-methylmorpholine (14.05 mL, 127.8 mmol) and 1,(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (24.5 g, 127.8 mmol). After 3 h of stirring at room temperature, the medium was washed with aqueous HCl (0.2 N), with water, with brine, dried over sodium sulphate, filtered and concentrated in vacuo to afford *tert*-butyl (S)-3-(((allyloxy)carbonyl)amino)-4-(methoxy(methyl)amino)-4-oxo-butanoate (29.2 g, 86%) as a yellow oil: LCMS ESI⁺ *m/z* 317.3 (M+H)⁺; ¹H NMR (CDCl₃, 500 MHz) δ 5.85–5.93 (m, 1H), 5.59 (br d, *J* = 8.5 Hz, 1H), 5.30 (m, 1H), 5.19 (m, 1H), 5.00 (m, 1H), 4.56 (m, 2H), 3.78 (s, 3H),

3.21 (s, 3H), 2.70 (dd, $J = 15.0$ Hz and 5.5 Hz, 1H), 2.54 (dd, $J = 15.0$ Hz and 6.5 Hz, 1H), 1.43 (s, 9H).

Step 3: A solution of lithium aluminium hydride (2 N in THF, 5.93 mL, 11.8 mmol) was added dropwise to a cooled (-78°C) solution of *tert*-butyl (S)-3-(((allyloxy)carbonyl)amino)-4-(methoxy(methyl)amino)-4-oxobutanoate (5.0 g, 15.8 mmol) in anhydrous THF (65 mL). The mixture was stirred at -78°C for 2 h, then aqueous HCl (1 N) was slowly added to the medium and the temperature was allowed to warm to 0°C . The mixture was diluted with EtOAc. The aqueous layer was extracted (EtOAc, two times). The combined organic layer was washed with aqueous HCl (0.5 N), with brine, dried over sodium sulphate, filtered and concentrated in vacuo to afford *tert*-butyl (S)-3-(((allyloxy)carbonyl)amino)-4-oxobutanoate (3.4 g, 83%) as a pale pink oil: ^1H NMR (CDCl_3) δ 9.66 (s, 1H), 5.83 (br d, 1H), 5.99–5.82 (m, 1H), 5.33 (m, 1H), 5.24 (m, 1H), 4.61 (m, 2H), 4.36 (m, 1H), 2.96 (dd, $J = 17.2$ Hz and 4.5 Hz, 1H), 2.76 (dd, $J = 17.2$ Hz and 5.1 Hz, 1H), 1.43 (s, 9H).

Step 4: To a freshly prepared solution of *tert*-butyl (S)-3-(((allyloxy)carbonyl)amino)-4-oxobutanoate (3.40 g, 13.23 mmol) in absolute ethanol (11 mL) were added, under Argon atmosphere, triethyl orthoformate (5.62 mL, 33.09 mmol), *p*-toluenesulfonic acid (45 mg, 0.26 mmol) and 3 Å molecular sieves. After stirring at room temperature overnight, the mixture was filtered over a pad of Celite and rinsed with EtOH. The filtrate was concentrated under reduced pressure and co-evaporated with toluene (three times). Purification of the residue by flash chromatography on silica gel (cyclohexane-EtOAc 9/1 to 8/2) afforded the title compound (**6**, 4.05 g, 92%) as a colorless oil: ^1H NMR (CDCl_3) δ 5.83–6.00 (m, 1H), 5.30 (d, $J = 17.4$ Hz, 1H), 5.23 (br d, $J = 8.5$ Hz, 1H), 5.21 (m, 1H), 4.56 (m, 2H), 4.49 (m, 1H), 4.22–4.11 (m, 1H), 3.78–3.65 (m, 2H), 3.61–3.48 (m, 2H), 2.56 (dd, $J = 15.6$ Hz and 5.7 Hz, 1H), 2.45 (dd, $J = 15.6$ Hz and 7.2 Hz, 1H), 1.44 (s, 9H), 1.21 (m, 6H); ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 170.12, 155.44, 133.78, 116.66, 102.57, 79.66, 64.16, 63.39, 62.22, 50.44, 36.09, 27.69, 15.15; $[\alpha]_D^{20} = -18.3^{\circ}$ ($c = 16$ g/L, MeCN); HRMS: $(\text{M}+\text{H})^+$ calculated for $\text{C}_{16}\text{H}_{29}\text{NO}_6$ 331.1995; found 354.1886 $(\text{M}+\text{Na})^+$, 685.3883 $(2\text{M}+\text{Na})^+$, 230.1022 cyclized warhead eg., $(\text{M}(-\text{OEt}, -\text{tBu}) + \text{H})^+$.

4.1.6. *N*-((3*R*)-1-((2*S*)-1-(((3*S*)-2-Ethoxy-5-oxotetrahydro-furan-3-yl)amino)-1-oxopropan-2-yl)-2,5-dioxopyrrolidin-3-yl)-2-naphthamide (**7**)

To a degassed solution (argon sparging, 5 min) of *N*-Alloc protected warhead **6** (803 mg, 2.42 mmol) and dimethylbarbituric acid (315 mg, 2.02 mmol) in DCM (15 mL) at room temperature was added $\text{Pd}(\text{PPh}_3)_4$ (42 mg, 36 μmol , 0.015 eq). The solution was stirred at room temperature for 15 min (TLC (cyclohexane/EtOAc, 7/3) showed deprotection was complete). At the same time, the acid derivative obtained above (687 mg, 2.02 mmol) in solution in a mixture DCM/DMF (8 mL/7 mL) at 0°C was treated with EDCl (580 mg, 3.03 mmol) and HOBt (273 mg, 2.02 mmol). The reaction mixture was stirred for 5 min. Then, the solution of the amine prepared above was added dropwise. The reaction mixture was stirred at room temperature for 16 h. After removal of solvents, the residue was taken-up in EtOAc and aq. saturated NH_4Cl . After separation, aqueous phase was extracted with EtOAc. The combined organics were washed sequentially with aq. sat. NaHCO_3 , 1N HCl and brine, then dried over Na_2SO_4 , filtered and concentrated under vacuum. The residue was purified by silica gel flash chromatography (cyclohexane/EtOAc, gradient of 1/0 to 1/4). The expected product was isolated as a beige solid (830 mg, 72%); $R_f = 0.3$ (cyclohexane/EtOAc 2/3); LCMS ($t_R = 3.67$ min, purity = 100%) ESI^+ m/z 570 $(\text{M}+\text{H})^+$; ^1H NMR (500 MHz, CDCl_3) δ 8.31 (s, 1H), 7.84–7.72 (m, 5H), 7.54–7.46 (m, 2H), 7.16 (d, $J = 8.5$ Hz, 1H), 4.92 (q, $J = 7.3$ Hz, 1H), 4.68 (m, 1H), 4.60–4.52 (m, 2H), 3.83–3.70 (m, 2H), 3.65–3.55 (m, 2H), 3.24 (dd, $J = 18.5$, 9.5 Hz, 1H), 2.99 (dd, $J = 18.5$,

5.5 Hz, 1H), 2.70–2.55 (m, 2H), 1.71 (d, $J = 7.0$ Hz, 3H), 1.39 (s, 9H), 1.24 (t, $J = 7.0$ Hz, 3H), 1.23 (t, $J = 7.0$ Hz, 3H).

4.1.7. *N*-((3*R*)-1-((2*S*)-1-(((3*S*)-2-Ethoxy-5-oxotetrahydro-furan-3-yl)amino)-1-oxopropan-2-yl)-2,5-dioxopyrrolidin-3-yl)-2-naphthamide (**8**)

To a solution of *N*-((3*R*)-1-((2*S*)-1-(((3*S*)-2-ethoxy-5-oxotetrahydrofuran-3-yl)amino)-1-oxopropan-2-yl)-2,5-dioxopyrrolidin-3-yl)-2-naphthamide (830 mg, 1.46 mmol) in DCM (15 mL) at 0°C was added TFA (1.12 mL, 14.6 mmol, 10 eq). The mixture was stirred for 45 min at 0°C , then the solvent and excess TFA were removed. The residue was co-evaporated with DCM, then purified by flash chromatography (40 g silica column, cyclohexane/AcOEt, gradient of 1/0 to 0/1) and then on preparative TLC (cyclohexane/AcOEt 1/4) to give the desired product as a white solid (405 mg, 59%); LCMS ($t_R = 3.18$ min, purity = 93%) ESI^+ m/z 468.1 $(\text{M}+\text{H})^+$; ^1H NMR (CDCl_3 , 500 MHz) δ 8.38 (s, 1H), 7.90 (d, $J = 8.0$ Hz, 1H), 7.85 (d, $J = 7.0$ Hz, 1H), 7.80–7.65 (m, 4H), 7.60–7.40 (m, 2H), 5.50 (s, 1H), 4.95 (q, $J = 7.3$ Hz, 1H), 4.44 (t, $J = 6.7$ Hz, 1H), 4.29 (m, 1H), 3.85 (m, 1H), 3.66 (m, 1H), 3.18 (dd, $J = 18.5$, 9.5 Hz, 1H), 3.02 (dd, $J = 18.5$, 5.0 Hz, 1H), 2.91 (dd, $J = 18.0$, 8.0 Hz, 1H), 2.60 (dd, $J = 18.0$, 2.0 Hz, 1H), 1.63 (d, $J = 7.0$ Hz, 3H), 1.22 (t, $J = 7.2$ Hz, 3H).

4.1.8. *N*-((3*R*)-1-((2*S*)-1-(((3*S*)-2-Hydroxy-5-oxotetrahydro-furan-3-yl)amino)-1-oxopropan-2-yl)-2,5-dioxopyrrolidin-3-yl)-2-naphthamide (**1**)

To a solution of *N*-((3*R*)-1-((2*S*)-1-(((3*S*)-2-ethoxy-5-oxotetrahydrofuran-3-yl)amino)-1-oxopropan-2-yl)-2,5-dioxopyrrolidin-3-yl)-2-naphthamide (330 mg, 0.706 mmol) in MeCN (3.5 mL) at 0°C was added aq. 2N HCl (3.5 mL, 7.1 mmol, 10 eq). The reaction mixture was stirred at room temperature for 4 h, then extracted with EtOAc. The organic phase was then dried over Na_2SO_4 , filtered and concentrated under vacuum. The residue was purified by preparative HPLC (eluent MeCN/ $\text{H}_2\text{O}/\text{HCO}_2\text{H}$). The pure fractions were frozen and lyophilised to yield expected product (100 mg, 32%) as a white solid: LCMS ($t_R = 3.97$ min, purity = 100%) ESI^+ m/z 440 $(\text{M}+\text{H})^+$; ^1H NMR (500 MHz, MeOD) δ 8.45 (s, 1H), 8.03–7.90 (m, 4H), 7.63–7.55 (m, 2H), 4.83 (overlap with HDO signal, 1H), 4.65 (dd, $J = 10.0$, 4.0 Hz, 1H), 4.63 (m, 1H), 4.36 (m, 1H), 3.18 (dd, $J = 18.0$, 9.5 Hz, 1H), 2.89 & 2.86 (2 t, $J = 4.8$ Hz, 1H), 2.67 & 2.64 (2 dd, $J = 6.0$, 4.0 Hz, 1H), 2.59–2.51 (m, 1H), 1.60 & 1.61 (2 d, $J = 7.5$ Hz, 3H); ^{13}C NMR ($\text{DMSO}-d_6$) δ 175.43, 174.80, 168.71, 166.81, 134.49, 132.13, 129.01, 128.20, 128.19, 128.10, 127.73, 127.01, 123.80, 102.69, 52.93, 49.20, 48.13, 35.24, 32.79, 13.57; HRMS: $(\text{M}+\text{H})^+$ calculated for $\text{C}_{22}\text{H}_{21}\text{N}_3\text{O}_7$ 440.1379; found 440.14505.

4.2. *N*-((3*R*)-1-((2*S*)-1-(((3*S*)-2-hydroxy-5-oxotetrahydrofuran-3-yl)amino)-1-oxopropan-2-yl)-2,6-dioxopiperidin-3-yl)-2-naphthamide (**2**) was prepared in 7 steps

4.2.1. *tert*-Butyl (S)-2-((*R*)-3-(((benzyloxy)carbonyl)amino)-2,6-dioxopiperidin-1-yl)propanoate

K_2CO_3 (55.3 mg, 0.400 mmol) was added to a solution of (*R*)-3-*N*-Cbz-amino-2,6-dioxo-piperidine (**9**, 100 mg, 0.381 mmol) and *tert*-butyl (*R*)-2-(((trifluoromethyl)-sulfonyl)oxy)propanoate (117 mg, 0.419 mmol) in anhydrous MeCN (2.0 mL) at 0°C . The reaction mixture was allowed to stir at r.t. for 30 h. The mixture was diluted with EtOAc, washed with 1N HCl (aq) and the organic phase was dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by preparative TLC (cyclohexane/EtOAc, 1/1) to give the title compound as yellow oil (79 mg, 53%); LCMS ($t_R = 3.47$ min, purity = 100% (ESLD) m/z (ESI^+) 408.2 $(\text{M}+\text{NH}_4^+)^+$, 391.1 $(\text{M}+\text{H})^+$, 335.1 $(\text{M}-\text{C}_4\text{H}_9)^+$; ^1H NMR (CDCl_3 , 500 MHz) δ 7.28–7.40 (m, 5H), 5.70 (br s, 1H), 5.09–5.24 (m, 1H, superposition with benzylic CH_2), 5.13 (s, 2H), 4.24–4.40 (m, 1H), 2.62–2.93 (m,

2H), 2.44–2.59 (m, 1H), 1.74–1.92 (m, 1H), 1.43 (m, 3H, superposition avec *t*-Bu), 1.40 (s, 9H); Chiral HPLC (Chiralpak AD, *n*-heptane/2-propanol (80/20), 1 mL/min. t_R = 9.91 (minor) & 14.27 (major), ratio 2/98, e.e. = 96%.

4.2.2. (S)-2-((R)-3-(((benzyloxy)carbonyl)amino)-2,6-dioxopiperidin-1-yl)propanoic acid (**10**)

Under argon, to a solution of *tert*-butyl (S)-2-((R)-3-(((benzyloxy)carbonyl)amino)-2,6-dioxopiperidin-1-yl)propanoate (412 mg, 1.06 mmol) in DCM (10 mL) at 0 °C was added TFA (2.44 mL, 31.66 mmol). The reaction mixture was stirred at room temperature for 4 h. TLC monitoring (cyclohexane/EtOAc, 1/1) showed complete conversion. The reaction mixture was concentrated in vacuum. The residue was co-evaporated with DCM 4 times to remove residual TFA. The residue was taken-up in EtOAc and precipitated in pentane. The off-white solid was filtered, rinsed with pentane and then evaporated to dryness to give expected product (416 mg, quant) that was used without further purification: LCMS (t_R = 2.79 min, purity = 100%) ESI[−] m/z 333.1 (M-H)[−]; ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.54 (br s, 1H), 7.70 (d, *J* = 8.7 Hz, 1H), 7.28–7.42 (m, 5H), 5.07 (s, 2H), 5.02–5.14 (m, 1H), 4.35–4.55 (m, 1H), 2.82–3.00 (m, 1H), 2.60–2.77 (m, 1H), 1.90–2.02 (m, 2H), 1.29 (d, *J* = 6.9 Hz, 3H).

4.2.3. *tert*-Butyl (S)-3-((S)-2-((R)-3-(((benzyloxy)carbonyl)amino)-2,6-dioxopiperidin-1-yl)propanamido)-4,4-diethoxybutanoate (**11**)

To a degassed solution (argon bubbling, 5 min) of Warhead **6** (419 mg, 1.27 mmol, 1.2 eq.) and dimethylbarbituric acid (132 mg, 0.845 mmol, 0.8 eq.) in DCM (10 mL) at room temperature was added Pd(PPh₃)₄ (12 mg, 10.6 μ mol, 0.01 eq.). The solution was stirred at room temperature for 10 min (TLC monitoring (cyclohexane/EtOAc, 7/3) showed deprotection was complete). The acid derivative (353 mg, 1.06 mmol) in solution in a mixture DCM/DMF (5 mL/1 mL) was then added followed by HOBT (143 mg, 1.06 mmol) and EDCI (243 mg, 1.27 mmol). The reaction mixture was stirred at room temperature for 20 h. After removal of solvents, the residue was taken-up in EtOAc and aq. saturated NH₄Cl. After separation, aqueous phase was extracted with EtOAc. The combined organics were washed sequentially with aq. sat. NaHCO₃, 1N HCl, and brine, then dried over Na₂SO₄, filtered and concentrated under vacuum. The residue was purified by silica gel flash chromatography (cyclohexane/EtOAc, gradient from 1/0 to 1/4). Expected product was isolated as a white solid (371 mg, 62%); LCMS (t_R = 3.75 min, purity = 90%) ESI⁺ m/z 564.4 (M+H)⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.30–7.40 (m, 5H), 6.73 & 6.58 (2d, *J* = 8.6 Hz, 1H), 5.70 (br s, 1H), 5.15–5.28 (m, 1H), 5.13 (s, 2H), 4.25–4.50 (m, 3H), 3.60–3.80 (m, 2H), 3.48–3.60 (m, 2H), 2.67–2.95 (m, 2H), 2.37–2.58 (m, 3H), 1.90–2.07 (m, 1H), 1.50 (d, *J* = 6.9 Hz, 3H), 1.41 (s, 9H), 1.13–1.23 (m, 6H).

4.2.4. *tert*-Butyl (S)-3-((S)-2-((R)-3-amino-2,6-dioxopiperidin-1-yl)propanamido)-4,4-diethoxybutanoate

To a degassed solution of *tert*-butyl (S)-3-((S)-2-((R)-3-(((benzyloxy)carbonyl)amino)-2,6-dioxopiperidin-1-yl)propan-amido)-4,4-diethoxybutanoate (371 mg, 0.658 mmol) in EtOH (20 mL) 20% Pd(OH)₂/C (100 mg) was added. The reaction mixture was hydrogenated under 1 atm of H₂ at room temperature for 6 h. The reaction mixture was then filled with argon. TLC monitoring of the reaction (cyclohexane/EtOAc, 3/7) showed a complete conversion. The medium was filtered on Celite and rinsed with EtOH. After evaporation to dryness, the brown solid obtained (290 mg, quant.) was used without further purification in the next step: LCMS (t_R = 2.56 min, purity = 90%), ESI⁺ m/z 430.3 (M+H)⁺; ¹H NMR (300 MHz, CDCl₃) δ 6.68 (d, *J* = 8.5 Hz, 1H), 5.16–5.28 (m, 1H),

4.46–4.54 (m, 1H), 4.27–4.38 (m, 1H), 3.42–3.80 (m, 5H), 2.80–2.93 (m, 1H), 2.60–2.77 (m, 1H), 2.38–2.56 (m, 2H), 1.19 (t, *J* = 7.0 Hz, 6H), 1.43 (s, 9H), 1.50 (br d, 3H), 1.64–1.77 (m, 2H), 1.80–1.98 (m, 1H), 2.16–2.28 (m, 1H).

4.2.5. *tert*-Butyl (S)-3-((S)-2-((R)-3-(2-naphthamido)-2,6-dioxopiperidin-1-yl)propanamido)-4,4-diethoxybutanoate (**12**)

To a solution of the *tert*-butyl (S)-3-((S)-2-((R)-3-(((benzyloxy)carbonyl)amino)-2,6-dioxopiperidin-1-yl)propan-amido)-4,4-diethoxybutanoate obtained above (283 mg, 0.659 mmol) in THF (5 mL) cooled to 0 °C, were successively added DIPEA (0.207 mL, 1.19 mmol) and 2-naphthoyl chloride (163 mg, 0.856 mmol). The reaction mixture was stirred at room temperature for 4 h. LCMS monitoring showed disappearance of starting material. The reaction mixture was then directly concentrated under reduced pressure with silica. The residue was purified by silica gel flash chromatography (cyclohexane/EtOAc, gradient of 9/1 to 3/7) to give the expected product (318 mg, 83%) as a pink solid: LCMS (t_R = 3.15 min, purity = 99%) ESI⁺ m/z 584.2 (M+H)⁺; ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.01 & 9.13 (2d, *J* = 8.5 Hz, 1H), 8.50 (s, 1H), 7.92–8.10 (m, 4H), 7.58–7.68 (m, 2H), 7.48 & 7.57 (2d, *J* = 8.4 Hz, 1H), 4.92–5.12 (m, 1.5H), 4.80–4.92 (m, 0.2H), 4.42 (d, *J* = 5.1 Hz, 1H), 4.36–4.26 (m, 0.3H), 4.25–4.12 (m, 1H), 3.68–3.39 (m, 4H), 2.54–2.95 (m, 2H), 2.00–2.50 (m, 4H), 1.30–1.41 (s and m, 9H and 3H), 1.04–1.13 (m, 6H).

4.2.6. *N*-((3R)-1-((2S)-1-(((3S)-2-ethoxy-5-oxotetrahydrofuran-3-yl)amino)-1-oxopropan-2-yl)-2,6-dioxopiperidin-3-yl)-2-naphthamide

To *tert*-butyl (S)-3-((S)-2-((R)-3-(2-naphthamido)-2,6-dioxopiperidin-1-yl)propanamido)-4,4-diethoxybutanoate (**12**, 314 mg, 0.534 mmol) suspended in DCM (4 mL) at 0 °C was added TFA (414.5 μ L, 5.38 mmol). After 1 h of stirring at 0 °C, the solvent and excess TFA were evaporated. The residue was taken-up in EtOAc and washed with aq. sat. NaHCO₃ solution. The aqueous phase was extracted 5 times with EtOAc. The combined organics were dried over Na₂SO₄, filtered and concentrated under vacuum. The residue was purified by flash chromatography on silica gel (cyclohexane/EtOAc, gradient of 1/1 to 0/1) to yield expected product (195 mg, 75%) as a white solid: LCMS (t_R = 3.10 min, purity = 93%) ESI⁺ m/z 482.2 (M+H)⁺; ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.02–9.14 (m, 1H), 8.50 (s, 1H), 8.09–8.15 (m, 0.6H), 7.90–8.09 (m, 4H), 7.56–7.69 (m, 2H), 5.53 (d, *J* = 5.1 Hz, 0.3H), 5.30–5.35 (m, 0.5H), 4.80–5.12 (m, 1.7H), 4.50–4.65 (m, 0.3H), 4.05–4.15 (m, 1H), 3.52–3.80 (m, 2H), 2.54–3.06 (m, 3H), 2.00–2.50 (m, 3H), 1.24–1.39 (m, 3H), 1.10–1.20 (m, 3H).

4.2.7. *N*-((3R)-1-((2S)-1-(((3S)-2-hydroxy-5-oxotetrahydrofuran-3-yl)amino)-1-oxopropan-2-yl)-2,6-dioxopiperidin-3-yl)-2-naphthamide (**2**)

To a suspension of *N*-((3R)-1-((2S)-1-(((3S)-2-ethoxy-5-oxotetrahydrofuran-3-yl)amino)-1-oxopropan-2-yl)-2,6-dioxopiperidin-3-yl)-2-naphthamide (190 mg, 394.6 μ mol) in acetonitrile (2.5 mL) was added aq. 2N HCl (1.97 mL, 3.95 mmol, 10 eq.). After 6 h of stirring at room temperature, LCMS monitoring showed complete conversion. The reaction mixture was diluted with EtOAc. The phases were separated and the aqueous phase was extracted with EtOAc (5 $\times$ 6 mL). The combined organics were then dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue (173 mg) was purified by preparative HPLC (MeCN/H₂O/HCO₂H 10 mM). The pure fractions were frozen and lyophilised to yield expected product **2** (93 mg, 52%) as a white solid: LCMS (t_R = 4.06 min, purity = 97%) ESI⁺ m/z 454.5 (M+H)⁺; ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.95–9.15 (m, 1H), 8.51 (s, 1H), 7.93–8.10 (m, 4H), 7.72 (m, 1H), 7.56–7.68 (m, 2H), 5.50 (m, 1H),

4.76–5.15 (m, 2H), 3.95–4.25 (m, 1H), 2.67–3.02 (m, 3H), 2.38–2.50 (m, 1H), 2.15–2.37 (m, 1H), 2.20–2.50 (m, 1H), 1.95–2.10 (m, 1H), 1.31 & 1.36 (2d, $J = 6.9$ Hz, 3H).

4.3. *N*-(3-(1-(((3*S*)-2-Hydroxy-5-oxotetrahydrofuran-3-yl)carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)benzamide (**16**) was prepared in 12 steps

4.3.1. 1-Ureidocyclopropane-1-carboxylic acid (**18**)

A suspension of 1-aminocyclopropane-1-carboxylic acid (**17**, 120 g, 1.19 mol, 1.0 eq.) and potassium cyanate (150 g, 1.85 mol, 1.56 eq.) in water (500 mL) was heated to reflux temperature during 3 h. Upon completion the mixture was cooled to 3 °C and aqueous hydrochloric acid 37% (200 mL, 2.03 eq.) was slowly added (CARE: vigorous CO₂ gas release) to adjust to pH 2 and a white precipitate appeared. The white precipitate was filtered, washed with iced water (250 mL) acetone (3 × 255 mL) and dried. 1-Ureidocyclopropane-1-carboxylic acid (**18**, 133.7 g, 78%) was obtained as a white solid: LCMS ($t_R = 0.22$ min, purity = 100%) ESI⁺ m/z 144.94 (M+H)⁺, 166.99 (M+Na)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 6.61 (s, 1H), 5.55 (s, 2H), 1.26 (q, $J = 4.2$ Hz, 2H), 0.93 (q, $J = 4.2$ Hz, 2H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 173.80, 158.71, 51.96, 17.47.

4.3.2. Allyl 1-ureidocyclopropane-1-carboxylate (**19**)

To a suspension of 1-ureidocyclopropane-1-carboxylic acid (**18**, 122 g, 0.85 mol, 1 eq.) in a tetrahydrofuran (1 L)/water (100 mL) mixture was added *N,N*-diisopropylethylamine (175 mL, 1.02 mol, 1.2 eq.) and allyl bromide (88 mL, 1.02 mol, 1.2 eq.). The reaction mixture was heated to reflux during 18 h. Upon completion mixture was cooled to room temperature then saturated aqueous ammonium chloride solution (300 mL) and ethyl acetate (1 L) were added. The aqueous phase was extracted with ethyl acetate (2 × 1 L) and 2-methyltetrahydrofuran (5 × 1 L). The organic phases were gathered and concentrated under reduced pressure to 1.5 L. The organic phase was washed with saturated aqueous ammonium chloride solution (2 × 100 mL), dried over MgSO₄, filtered, and concentrated under reduced pressure. The white solid obtained was triturated in diisopropyl ether (1.25 L), filtered, washed with diisopropyl ether and dried. Allyl 1-ureidocyclopropane-1-carboxylate (**19**, 67.8 g, 68%) was obtained as a white solid: LCMS ($t_R = 0.50$ min, purity = 90%) ESI⁺ m/z 184.98 (M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 6.66 (s, 1H), 5.88 (ddt, $J = 17.3, 10.3, 5.0$ Hz, 1H), 5.58 (s, 2H), 5.39–5.11 (m, 2H), 4.53 (dt, $J = 5.0, 1.7$ Hz, 2H), 1.33 (q, $J = 4.3$ Hz, 2H), 1.02 (q, $J = 4.4$ Hz, 2H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 172.97, 158.73, 132.65, 117.10, 64.66, 33.49, 17.51; HRMS: (M+H)⁺ calculated for C₈H₁₂N₂O₃ 185.0848; found 185.0921.

4.3.3. Allyl (*E/Z*) 1-(3-(3-ethoxy-2-nitro-3-oxoprop-1-en-1-yl)ureido)cyclopropane-1-carboxylate (**20**)

To a suspension of allyl 1-ureidocyclopropane-1-carboxylate (**19**, 95.0 g, 0.52 mol, 1 eq.) in toluene (500 mL) were successively added ethyl nitroacetate (69 mL, 0.62 mol, 1.2 eq.) and triethyl orthoformate (103 mL, 0.62 mol, 1.2 eq.). The reaction mixture was heated to reflux during 15 h. To complete the reaction 2 further additions of ethyl nitroacetate (2 × 12 mL, 2 × 0.2 eq.) and triethyl orthoformate (2 × 17 mL, 2 × 0.2 eq.) were added. Upon reaction completion heptane (1 L) was slowly added at reflux temperature. The heating was stopped and the reaction mixture slowly crystallised. The yellow solid was filtered, washed with heptane and dried. Allyl 1-(3-(3-ethoxy-2-nitro-3-oxoprop-1-en-1-yl)ureido)-cyclopropane-1-carboxylate (**20**, 135 g, 79%) was obtained as a yellow solid as ~7/3 mixture of *E/Z* isomers: LCMS ($t_R = 1.04$ min, purity = 100%) ESI⁺ m/z 328.00 (M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.81 (d, $J = 13.2$ Hz, 0.7 H), 10.29 (d, $J = 12.7$ Hz, 0.3 H),

8.93 (s, 0.3H), 8.87 (d, $J = 12.7$ Hz, 0.3H), 8.76 (s, 0.7H), 8.50 (d, $J = 13.3$ Hz, 0.7H), 5.89 (m, 1H), 5.28 (dq, $J = 17.2, 1.7$ Hz, 1H), 5.21 (dq, $J = 10.5, 1.5$ Hz, 1H), 4.62–4.50 (m, 2H), 4.33 (q, $J = 7.1$ Hz, 0.8 H), 4.23 (q, $J = 7.1$ Hz, 1.2 H), 1.48 (q, $J = 4.7$ Hz, 2H), 1.37–1.16 (m, 5H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 171.24, 159.93, 152.08, 141.43, 132.42, 119.58, 117.53, 65.24, 61.21, 33.60, 17.11, 14.07; HRMS: (M+H)⁺ calculated for C₁₃H₁₇N₃O₇ 328.1066; found 328.1137.

4.3.4. Allyl 1-(5-nitro-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)cyclopropane-1-carboxylate (**21**)

A suspension of allyl 1-(3-(3-ethoxy-2-nitro-3-oxoprop-1-en-1-yl)ureido)cyclopropane-1-carboxylate (**20**, 135 g, 0.41 mol, 1 eq.) and cesium carbonate (296 g, 0.91 mol, 2.2 eq.) in acetonitrile (1.35 L) was heated under reflux for 30 min. The reaction mixture was cooled to room temperature and diisopropyl ether (500 mL) was added. The organic phase was discarded and the basic aqueous phase was cooled to 5 °C and pH was adjusted to 2 with aqueous hydrochloric acid 37% [CARE: Vigorous release of CO₂(g)]. The acidic aqueous phase was extracted with dichloromethane (2 × 1 L) and the organic phase was dried over magnesium sulphate and evaporated under reduce pressure. A brown oil was obtained and precipitated in an isopropanol/diisopropyl ether mixture. The solid was filtered, washed with diisopropyl ether (500 mL) and dried. Allyl 1-(5-nitro-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)cyclopropane-1-carboxylate (**21**, 83.1 g, 73%) was obtained as an orange solid: LCMS ($t_R = 0.83$ min, purity = 100%) ESI⁺ m/z 280.07 (M-H)[−]; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.65 (s, 1H), 8.97 (s, 1H), 5.85 (m, 1H), 5.28–5.13 (m, 2H), 4.58 (m, 2H), 1.83–1.72 (m, 2H), 1.41 (m, 2H).

4.3.5. Allyl 1-(3-isopropyl-5-nitro-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)cyclopropane-1-carboxylate (**22**)

To a stirred suspension of 1-(5-nitro-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl)-cyclopropanecarboxylic acid allyl ester (**21**, 4.58 g, 16.3 mmol, 1.00 eq.) and K₂CO₃ (3.38 g, 0.02 mol, 1.50 eq.) in DMF (91.6 mL) at r.t., was added 2-iodopropane (8.15 mL, 81.5 mmol, 5.00 eq.) and the suspension was stirred at r.t. for 24 h. The reaction mixture was slowly added to water and the product was extracted in EtOAc (3 × 100 mL). The organic phases were combined, washed with water (3 × 50 mL), dried over MgSO₄ and concentrated to dryness. The residue was purified by flash chromatography (silica gel, gradient 0–20% EtOAc in heptane) to afford 1-(3-isopropyl-5-nitro-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl)-cyclopropanecarboxylic acid allyl ester (**22**, 2.41 g, 46%) as a white solid: LCMS ($t_R = 1.04$ min, purity = 99%) ESI⁺ m/z 324.5 (M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.13 (s, 1H), 5.97–5.69 (m, 1H), 5.31–5.05 (m, 2H), 4.79–4.68 (m, 1H), 4.58 (ddt, $J = 8.5, 4.9, 1.7$ Hz, 2H), 1.91–1.59 (m, 2H), 1.50–1.10 (m, 8H).

4.3.6. Allyl 1-(5-amino-3-isopropyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)cyclopropane-1-carboxylate (**23**)

A stirred suspension of 1-(3-isopropyl-5-nitro-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl)-cyclopropanecarboxylic acid allyl ester (**22**, 2.41 g, 7.45 mmol, 1.00 eq.), ammonium chloride (0.20 g, 3.73 mmol, 0.50 eq.), iron (1.67 g, 29.8 mmol, 4.00 eq.) in a mixture of EtOH (14.5 mL), THF (14.5 mL) and water (14.5 mL) was heated at 70 °C for 1 h. The reaction mixture was cooled to r.t., filtered through a pad of Celite and washed with EtOH (5 × 5 mL). The filtrate was concentrated to dryness to afford 1-(5-amino-3-isopropyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl)-cyclopropanecarboxylic acid allyl ester (**23**, 2.31 g, 98%) as an orange gum: LCMS ($t_R = 0.99$ min, purity = 100%), ESI⁺ m/z 294.16 (M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 6.96 (s, 1H), 5.92–5.75 (m, 1H), 5.28–5.08 (m, 2H), 4.79–4.63 (m, 1H), 4.61–4.42 (m, 2H), 4.09 (s, 2H), 1.83–1.61 (m, 2H), 1.41–1.30 (m, 2H), 1.25–1.15 (m, 6H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 170.51, 160.39, 149.39, 132.32, 122.42, 116.63, 115.19, 64.86, 47.04,

39.05, 35.46, 20.92, 20.48, 19.53, 19.33; HRMS (M+H)⁺ calculated for C₁₄H₁₉N₃O₄ 294.1375; found 294.1448.

4.3.7. 2-Methyl-4-(naphthalen-2-ylamino)benzoic acid (**24**)

Step 1: A stirred solution of 2-aminonaphthalene (2.38 g, 16.63 mmol, 1.00 eq.), 4-bromo-2-methyl-benzoic acid methyl ester (4.00 g, 17.5 mmol, 1.05 eq.), palladium(II) acetate (373 mg, 1.66 mmol, 0.10 eq.), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (1.92 g, 3.33 mmol, 0.20 eq.) and cesium carbonate (7.04 g, 21.6 mmol, 1.30 eq.) in 1,4-dioxane (38.1 mL) was degassed and purged with nitrogen then heated at 120 °C under microwave irradiation for 30 min. The reaction was concentrated to dryness and partitioned between DCM (50 mL) and water (5 mL). The organic phase was retained and the aqueous phase was washed with DCM (3 × 5 mL). The organic phases were combined, washed with water (10 mL), dried over MgSO₄ and concentrated to dryness to afford a pale yellow residue. The residue was triturated with a mixture of DCM and heptane to afford a solid that was collected by filtration and dried to a constant weight to afford 2-methyl-4-(naphthalen-2-ylamino)-benzoic acid methyl ester (4.30 g, 89%) as a pale brown solid: LCMS (t_R = 1.35 min, purity = 100%), ESI⁺ m/z 292.01 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.89 (s, 1H), 7.93–7.75 (m, 5H), 7.63 (d, J = 2.2 Hz, 1H), 7.44 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.40–7.29 (m, 2H), 7.05 (dd, J = 8.6, 2.4 Hz, 1H), 7.00 (d, J = 2.3 Hz, 1H), 3.78 (s, 3H), 2.50 (s, 3H under DMSO signal).

Step 2: To a stirred solution of 2-methyl-4-(naphthalen-2-ylamino)-benzoic acid methyl ester (4.00 g, 13.7 mmol, 1.00 eq.) in a mixture of THF (80.0 mL) and MeOH (20.0 mL), was added lithium hydroxide (1.0 M, 41.2 mL, 41.2 mmol, 3.00 eq.). The reaction mixture was stirred at 50 °C overnight, concentrated to a minimum volume and the residue was partitioned between DCM (30 mL) and water (5 mL). The pH of the aqueous phase was adjusted to 1 by the addition of HCl (aq) (1.0 M) resulting in a thick precipitate that was collected by filtration and dried to a constant weight to afford 2-methyl-4-(naphthalen-2-ylamino)benzoic acid (**24**, 3.50 g, 92%) as a beige solid: LCMS (t_R = 1.20 min, purity = 100%), ESI⁺ m/z 278.02 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.19 (br s, 1H), 8.82 (s, 1H), 7.98–7.72 (m, 4H), 7.61 (d, J = 2.3 Hz, 1H), 7.50–7.25 (m, 3H), 7.10–6.90 (m, 2H), 2.51 (s, 3H hidden by DMSO signal); ¹³C NMR (101 MHz, DMSO-d₆) δ 168.07, 146.95, 141.82, 139.60, 134.19, 132.88, 129.01, 127.51, 128.96, 126.66, 126.43, 123.72, 120.18, 117.95, 112.68, 112.31, 22.25; HRMS: (M+H)⁺ calculated for C₁₈H₁₅NO₂ 278.1102; found 278.1172.

4.3.8. Allyl 1-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)benzamido)-2,6-dioxo-3,6-dihydro-pyrimidin-1(2H)-yl)cyclopropane-1-carboxylate

To a stirred solution of 2-methyl-4-(naphthalen-2-ylamino)-benzoic acid (**24**, 520 mg, 1.88 mmol, 1.10 eq.) and *N*-methylmorpholine (375 μL, 3.41 mmol, 2.00 eq.) in DMF (10.0 mL) at r.t., was added COMU ([1-cyano-1-ethoxycarbonyl-meth-(*Z*)-ylideneaminoxy]-morpholin-4-yl-methylene)-dimethyl-ammonium hexafluorophosphate) (876 mg, 2.05 mmol, 1.20 eq.) and the reaction mixture was stirred at r.t. for 30 min 1-(5-amino-3-isopropyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl)-cyclopropanecarboxylic acid allyl ester (500 mg, 1.70 mmol, 1.00 eq.) in DMF (5.00 mL) was added and the reaction mixture was heated at 50 °C for 48 h. The reaction mixture was treated with a saturated solution of NaHCO₃(aq) and the product extracted with EtOAc (3 × 30 mL). The organic phases were combined and washed with water (3 × 10 mL), dried over MgSO₄ and concentrated to dryness. The crude product was purified by flash chromatography (silica gel, gradient of 0–100% EtOAc in heptane) to afford 1-(3-Isopropyl-5-[2-methyl-4-(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl)-cyclopropanecarboxylic acid allyl ester (850 mg, 90%) as a pale yellow solid: LCMS (t_R = 1.43 min,

purity = 100%), ESI⁺ m/z 533.22 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.98 (s, 1H), 8.69 (s, 1H), 8.30 (s, 1H), 7.93–7.68 (m, 4H), 7.57 (d, J = 2.2 Hz, 1H), 7.51 (d, J = 8.4 Hz, 1H), 7.42 (ddd, J = 8.2, 6.8, 1.4 Hz, 1H), 7.37–7.28 (m, 2H), 7.10–6.99 (m, 2H), 5.85 (ddt, J = 17.3, 10.7, 4.8 Hz, 1H), 5.33–5.01 (m, 2H), 4.77 (h, J = 6.7 Hz, 1H), 4.70–4.43 (m, 2H), 2.43 (s, 3H), 1.84–1.64 (m, 2H), 1.55–1.20 (m, 8H); ¹³C NMR (DMSO-d₆) δ 170.24, 159.94, 149.89, 145.30, 140.18, 138.35, 134.26, 132.27, 131.18, 129.61, 128.98, 128.70, 127.50, 126.50, 126.40, 126.19, 123.44, 120.58, 118.16, 116.88, 113.03, 112.76, 111.48, 65.04, 54.95, 48.38, 35.67, 20.93, 20.58, 19.48, 19.22; HRMS: (M+H)⁺ calculated for C₃₂H₃₂N₄O₅ 553.2372; found 553.2443.

4.3.9. 1-(3-Isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)-benzamido)-2,6-dioxo-3,6-dihydro-pyrimidin-1(2H)-yl)cyclopropane-1-carboxylic acid (**25**)

A stirred solution of 1-[3-isopropyl-5-[2-methyl-4-(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-cyclopropanecarboxylic acid allyl ester (840 mg, 1.52 mmol, 1.00 eq.), 1,3-dimethylbarbituric acid (380 mg, 2.43 mmol, 1.60 eq.) in DCM (42 mL) was degassed and purged with nitrogen and tetrakis(triphenylphosphine)palladium(0) (70.3 mg, 0.06 mmol, 0.04 eq.) was added. The reaction mixture was stirred at r.t. for 45 min, concentrated and purified by flash chromatography (silica gel, gradient of 0–10% MeOH in DCM) to afford 1-[3-isopropyl-5-[2-methyl-4-(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-cyclopropane-carboxylic acid (**25**, 470 mg, 60%) as a beige solid: LCMS (t_R = 1.23 min, purity = 99%), ESI⁺ m/z 513.14 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ ¹H NMR (400 MHz, DMSO-d₆) δ 12.6 (br s, 1H), 8.93 (s, 1H), 8.69 (s, 1H), 8.28 (s, 1H), 7.92–7.70 (m, 3H), 7.57 (d, J = 2.2 Hz, 1H), 7.51 (d, J = 8.3 Hz, 1H), 7.42 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.37–7.28 (m, 2H), 7.09–7.00 (m, 2H), 4.96–4.49 (m, 1H), 2.44 (s, 3H), 1.67 (m, 2H), 1.45–1.20 (m, 8H).

4.3.10. Allyl ((3*S*)-2-ethoxy-5-oxotetrahydrofuran-3-yl)-carbamate (**26**)

To a cooled (4 °C) solution of *tert*-butyl (*S*)-3-(((allyloxy)carbonyl)amino)-4,4-diethoxybutanoate (**6**, 5.0 g, 15.1 mmol) in DCM (20 mL) was added trifluoroacetic acid (11.6 mL, 151 mmol). After 30 min of stirring at room temperature, the mixture was concentrated under vacuum, then co-evaporated with EtOAc. Purification of the residue by flash chromatography on silica gel (cyclohexane-EtOAc, gradient of 95/5 to 6/4) afforded the title compound (2.45 g, 71%) as a pink oil as a 1:1.2 mixture of two diastereoisomers: LCMS ESI⁺ m/z 229.9 (M+H)⁺; ¹H NMR (CDCl₃, 500 MHz) δ 5.97–5.85 (m, 1H), 5.44 (d, J = 5.0 Hz, 0.5 H), 5.40 (br s, 0.5 H), 5.36–5.22 (m, 2.5H), 5.00 (br s, 0.5 H), 4.62–4.57 (m, 2H), 4.57–4.52 (br s, 0.5H), 4.20 (br t, J = 6.5 Hz, 0.5H), 3.95–3.83 (m, 1H), 3.69–3.62 (m, 1H), 3.01 (dd, J = 18.0 Hz and 7.5 Hz, 0.5H), 2.84 (dd, J = 17.0 Hz and 8.5 Hz, 0.5H), 2.46 (dd, J = 17.0 Hz and 10.5 Hz, 0.5H), 2.39 (dd, J = 18.0 Hz and 1.4 Hz, 0.5H), 1.26 (t, J = 7.0 Hz, 1.5H), 1.24 (t, J = 7.0 Hz, 1.5H); ¹³C NMR (101 MHz, DMSO-d₆) δ 174.71, 173.78, 155.73, 155.56, 133.58, 117.00, 107.23, 102.14, 65.16, 64.60, 52.85, 49.47, 32.89, 31.30, 14.90; HRMS: (M+H)⁺ calculated for C₁₀H₁₅NO₅ 229.0950; found 230.1023.

4.3.11. *N*-(3-(1-(((3*S*)-2-Ethoxy-5-oxotetrahydrofuran-3-yl)-carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)benzamide (**27**)

First Step: To a stirred solution of 1-[3-isopropyl-5-[2-methyl-4-(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-cyclopropanecarboxylic acid, (1.39 g, 2.71 mmol, 1.00 eq.) and *N*-methyl morpholine (358 μL, 3.25 mmol, 1.20 eq.) in a mixture of DCM (13.90 mL) and DMF (13.90 mL), HATU (1.24 g,

3.25 mmol, 1.20 eq.) was added and the reaction mixture was stirred at r.t. for 40 min.

Second Step: In parallel, a solution of ((*S*)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-carbamic acid allyl ester, (870 mg, 3.80 mmol, 1.40 eq.) et 1,3-dimethylbarbituric acid (593 mg, 3.80 mmol, 1.40 eq.) in a mixture of DCM (9.73 mL) and DMF (6.95 mL) at r.t. was degassed and purged with nitrogen then tetrakis(triphenylphosphine)palladium(0) (125 mg; 0.11 mmol; 0.04 eq.) was added. The reaction mixture was stirred at room temperature for 1 h.

Third step: The product, (4*S*)-4-amino-5-ethoxydihydrofuran-2(3*H*)-one, from the Alloc deprotection step was added to the pre-activated ester for the first step and the reaction mixture was stirred at room temperature overnight. The reaction mixture was treated with a saturated solution of NaHCO₃(aq) and the product extracted with EtOAc (2 × 50 mL). The organic phases were combined and washed with water (3 × 10 mL), dried over MgSO₄ and concentrated to dryness. The crude product was purified by flash chromatography (silica gel, gradient of 0–5% MeOH in DCM) to afford *N*-{3-[1-((*S*)-2-ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamo-yl)-cyclopropyl]-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl]-2-methyl-4-(naphthalen-2-ylamino)-benzamide (1.80 g, quant.) as an orange solid (mixture of diastereoisomers): LCMS (*t*_R = 1.27 min, purity = 99%), ESI⁺ *m/z* 640.30 (M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.93–8.77 (m, 1H), 8.71 (s, 1H), 8.43 (s, 1H), 7.88–7.72 (m, 3H), 7.67–7.53 (m, 2H), 7.49 (t, *J* = 8.3 Hz, 1H), 7.43 (ddd, *J* = 8.1, 6.8, 1.2 Hz, 1H), 7.36–7.27 (m, 2H), 7.12–6.98 (m, 2H), 5.50 (m, 0.5H), 5.22 (m, 0.5H), 4.60–4.70 (m, 0.5H), 4.10–4.20 (m, 0.5H), 3.70–3.80 (m, 1H), 3.55–3.65 (m, 1H), 2.80–3.20 (m, 0.5H), 2.72–2.56 (m, 1.5H), 2.44 (s, 3H), 1.60–1.70 (m, 2H), 1.40–1.26 (m, 6H), 1.10–1.20 (m, 5H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 174.01, 170.12, 169.94, 160.04, 167.21, 149.85, 145.42, 140.12, 138.30, 134.26, 129.47, 128.99, 128.73, 127.51, 126.51, 126.41, 123.48, 120.60, 118.21, 113.97, 112.84, 111.56, 102.12, 65.49, 48.10, 37.30, 37.22, 26.89, 21.04, 20.82, 20.57, 19.31; HRMS: (M+H)⁺ calculated for C₃₃H₃₇N₅O₇ 640.2693; found 640.27563.

4.3.12. *N*-(3-(1-(((3*S*)-2-Hydroxy-5-oxotetrahydrofuran-3-yl)carbamo-yl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)benzamide (16**)**

To a stirred solution of *N*-{3-[1-((*S*)-2-ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamo-yl)-cyclopropyl]-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl]-2-methyl-4-(naphthalen-2-ylamino)-benzamide (1.72 g, 2.69 mmol, 1.00 eq.) in MeCN (34.4 mL) was added HCl (aq) (2M, 13.4 mL, 26.9 mmol, 10.0 eq.) and the reaction mixture was stirred at room temperature for 5 h. The volatiles were eliminated under a flow of nitrogen and the residue was treated with a saturated aqueous solution of NaHCO₃ (pH 8) then diluted with EtOAc. The organic phase was discarded and the pH of the aqueous phase was adjusted to 5 with AcOH. The product was extracted in EtOAc (3 × 20 mL), the organic phases were combined, dried over MgSO₄ and concentrated to dryness. The resulting beige solid was crystallised from a mixture of EtOAc/toluene and the solid was recuperated by filtration and dried to a constant weight un a vacuum oven at 40 °C to afford *N*-(3-(1-(((3*S*)-2-hydroxy-5-oxotetrahydrofuran-3-yl)carbamo-yl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)benzamide (1.07 g, 65%) as an off-white solid: LCMS (*t*_R = 6.47 min, purity = 99%), ESI⁺ *m/z* 610.62 (M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.96–8.83 (m, 1H), 8.71 (s, 1H), 8.42 (s, 1H), 8.21 (s br, 1H), 7.87–7.73 (m, 3H), 7.58 (d, *J* = 2.3 Hz, 1H), 7.50 (d, *J* = 8.4 Hz, 1H), 7.43 (ddd, *J* = 8.2, 6.8, 1.3 Hz, 1H), 7.36–7.27 (m, 2H), 7.07 (dd, *J* = 8.3, 2.3 Hz, 1H), 7.03 (d, *J* = 2.3 Hz, 1H), 5.41 (s br, 1H), 4.78 (m, 1H), 4.15 (s br, 1H), 2.93 (m, 1H), 2.44 (s, 3H), 2.32 (m, 1H), 1.65 (m, 2H), 1.32 (dd, *J* = 13.1, 6.7 Hz, 6H), 1.16 (m, 2H); ¹³C NMR (400 MHz, DMSO-*d*₆) δ 167.31, 160.22, 149.87, 145.41, 140.15,

138.33, 134.28, 129.53, 129.02, 128.75, 128.48, 127.53, 126.53, 126.44, 126.14, 123.50, 120.61, 118.24, 113.99, 112.86, 111.55, 48.09, 39.07, 37.32, 20.98, 20.84, 20.60, 19.38; HRMS: (M+H)⁺ calculated for C₃₃H₃₃N₅O₇ 612.2380; found 612.2376; analytical chiral HPLC conditions (Chiralpak IC 4.6 mm*250 mm 5 μm column; eluent, *n*-heptane/EtOH/TEA (80/20/0.5); flow rate, 1.0 mL/min.; run time, 50 min; *t*_R = 12.287 min (*S* enantiomer), *t*_R = 20.100 min (*R* enantiomer), e.r. = 95:5 (*S*/*R*).

4.4. Checking the hydrolysis step for epimerization

4.4.1. (*S*)-4-Hydroxy-3-(1-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)benzamido)-2,6-dioxo-3,6-dihydro-pyrimidin-1(2*H*)-yl)cyclopropane-1-carboxamido)butanoic acid (29**)**

To a stirred solution of *N*-(3-(1-(((3*S*)-2-hydroxy-5-oxotetrahydrofuran-3-yl)carbamo-yl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)benzamide (**16**, 85.0 mg, 0.14 mmol) in MeOH (850 μL) was added portionwise NaBH₄ (10.5 mg, 0.28 mmol) at 0 °C and the reaction mixture was stirred at r.t. for 3 h 30 min. The reaction mixture was concentrated to dryness and the residue partitioned between EtOAc (50 mL) and water (5 mL). The organic phase was washed with water (1 × 5 mL), dried over MgSO₄ and concentrated to dryness. The residue was purified by mass-triggered preparative LCMS to afford (*S*)-4-hydroxy-3-(1-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)benzamido)-2,6-dioxo-3,6-dihydro-pyrimidin-1(2*H*)-yl)cyclopropane-1-carbox-amido)butanoic acid (**29**, 53.0 mg, 60%) as a cream coloured solid: LCMS (*t*_R = 1.15 min, purity = 98%, MS ESI⁺ *m/z* 612.55 (M-H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.83 (s, 1H), 8.71 (s, 1H), 8.40 (s, 1H), 7.92–7.67 (m, 3H), 7.58 (d, *J* = 2.1 Hz, 1H), 7.50–7.59 (m, 2H), 7.43 (ddd, *J* = 8.2, 6.8, 1.3 Hz, 1H), 7.37–7.28 (m, 2H), 7.10–7.01 (m, 2H), 4.76 (h, *J* = 6.9 Hz, 1H), 4.04 (m, 1H), 3.30–3.40 (m, 1H), 3.28–3.07 (m, 1H), 2.44 (s, 3H), 2.38–2.21 (m, 1H), 1.75–1.52 (m, 2H), 1.32 (m, 6H), 1.11 (s, 2H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 172.78, 169.06, 167.23, 160.13, 149.86, 145.39, 140.14, 134.26, 138.31, 129.48, 129.00, 128.73, 128.33, 127.51, 126.52, 126.41, 126.11, 123.47, 120.60, 118.23, 113.91, 112.85, 111.53, 62.51, 59.80, 48.79, 48.06, 37.48, 20.59, 18.82, 14.14; HRMS: (M+H)⁺ calculated for C₃₃H₃₅N₅O₇ 614.2536; found 614.2606; [α]_D²⁰ = −10.0° (c = 2.5 g/L, ACN); analytical chiral HPLC conditions (Chiralpak ID 4.6 mm*250 mm 5 μm column; eluent, *n*-heptane/EtOH/ACOH (80/20/0.1); flow rate, 1.5 mL/min.; run time, 50 min; *t*_R = 23.959 min (*S* enantiomer), *t*_R = 30.891 min (*R* enantiomer), e.r. = 95:5 (*S*/*R*).

4.4.2. (*S,E*)-4-((benzyloxy)imino)-3-(1-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)benzamido)-2,6-dioxo-3,6-dihydro-pyrimidin-1(2*H*)-yl)cyclopropane-1-carboxamido)butanoic acid (30**)**

To a stirred solution of *N*-(3-[1-((*S*)-2-hydroxy-5-oxo-tetrahydro-furan-3-ylcarbamo-yl)-cyclopropyl]-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)-benzamide (**16**, 103 mg, 0.17 mmol, 1.00 eq.) and pyridine (27.2 μL, 0.34 mmol, 2.00 eq.) in a mixture of THF (2.58 mL) and MeOH (2.58 mL), was added *O*-benzylhydroxylamine (52.3 μL, 0.51 mmol, 3.00 eq.) and the reaction mixture was heated at 80 °C for 1 h. The resulting solution was cooled to r.t. and partitioned between EtOAc (20 mL) and a saturated aqueous solution of NH₄Cl (5 mL). The organic phase was retained and the aqueous phase was washed with EtOAc (3 × 5 mL). The organic phases were combined, dried over MgSO₄ and concentrated to dryness and the residue was purified by flash chromatography (silica gel, gradient of 0–5% MeOH in DCM) to afford (*S,E*)-4-((benzyloxy)imino)-3-(1-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)benzamido)-2,6-

dioxo-3,6-dihydro-pyrimidin-1(2H)-yl)cyclopropane-1-carboxamido)-butanoic acid (**30**, 103 mg, 83%) as a cream coloured solid: LCMS (t_R = 1.30 min, purity = 100%), ESI[−] m/z 715.28 (M-H)[−]; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.35 (br s, 1H), 8.99–8.84 (m, 1H), 8.76 (s, 1H), 8.46 (d, J = 2.5 Hz, 1H), 8.22 (s, 1H), 8.04–7.75 (m, 3H), 7.63 (d, J = 2.5 Hz, 1H), 7.59–7.43 (m, 2H), 7.42–7.29 (m, 5H), 7.20–6.94 (m, 2H), 6.77 (d, J = 5.8 Hz, 1H), 5.13 (s, 0.5H), 5.04 (s, 1.5H), 4.93–4.67 (m, 1H), 4.05 (m, 1H), 2.81–2.62 (m, 2H), 2.49 (s, 3H), 1.68 (m, 2H), 1.37 (m, 6H), 1.26–1.11 (m, 2H); ¹³C NMR (DMSO-*d*₆) δ 171.50, 169.25, 167.24, 149.74, 145.38, 140.14, 138.32, 137.31, 134.26, 129.49, 128.99, 128.72, 128.41, 128.33, 127.86, 127.61, 127.51, 126.51, 126.41, 126.12, 123.47, 118.23, 120.59, 113.96, 112.84, 111.52, 75.24, 47.99, 46.01, 45.76, 40.13, 37.36, 20.99, 20.77, 20.58; HRMS (M+H)⁺ calculated for C₄₀H₄₀N₆O₇ 717.29585; found 717.30273; $[\alpha]_D^{20}$ = −10.0° (c = 2.5 g/L, ACN); analytical chiral HPLC conditions (Chiralpak ID 4.6 mm*250 mm 5 μ m column; eluent, *n*-heptane/EtOH/AcOH (80/20/0.1); flow rate, 1.5 mL/min.; run time, 50 min; t_R = 27.857 min (*S* enantiomer), t_R = 35.022 min (*R* enantiomer), e.r. = 93:7 (*S/R*).

4.5. *N*-(3-(1-(((3*S*)-2-Hydroxy-3-methyl-5-oxotetrahydro-furan-3-yl)amino)-1-oxopropan-2-yl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4-(quinoxalin-2-ylamino)benzamide (**36**) was prepared in 6 steps

4.5.1. (*S*)-2-(((9*H*-Fluoren-9-yl)methoxy)carbonyl)amino)-4-(*tert*-butoxy)-2-methyl-4-oxo-butanoic acid (**32**)

To a stirred solution of 10% w/v Na₂CO₃ (4.17 g, 39.4 mmol, 4.00 eq.), was added dropwise a solution of (*S*)-2-amino-2-methyl-succinic acid 4-*tert*-butyl ester (**31**, 2.00 g, 9.84 mmol, 1.00 eq.) in 1,4-dioxane (50 mL). After 10 min, a solution of Fmoc-OSu (3.98 g, 11.81 mmol, 1.20 eq.) in 1,4-dioxane (40 mL) was added to the reaction mixture and the resulting suspension was stirred at r.t. overnight. The reaction mixture was diluted with water (20 mL) and the pH adjusted to 6 with 1N HCl (aq). The product was extracted with EtOAc (3 $\times$ 50 mL) and the organic phases were combined and washed with water (3 $\times$ 20 mL), dried over MgSO₄ and concentrated to dryness to afford the crude product. The crude product was purified by flash chromatography (silica gel, gradient 0–10% MeOH in DCM) to afford (*S*)-2-(9*H*-fluoren-9-ylmethoxycarbonylamino)-2-methyl-succinic acid 4-*tert*-butyl ester (**32**, 3.54 g, 85%) as a white solid: LCMS (t_R = 1.22 min, purity = 99%), MS ESI[−] m/z 424 (M-H)[−]; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.8 (br s, 1H), 7.90 (d, J = 7.4 Hz, 1H), 7.71 (dd, J = 7.7, 2.6 Hz, 1H), 7.42 (td, J = 7.5, 1.1 Hz, 1H), 7.33 (t, J = 7.5 Hz, 1H), 4.34–4.13 (m, 3H), 2.87 (d, J = 14.3 Hz, 1H), 2.76–2.60 (m, 1H), 1.43 (s, 3H), 1.35 (s, 9H).

4.5.2. *tert*-Butyl (*S*)-3-(((9*H*-fluoren-9-yl)methoxy)carbonyl)-amino)-4-hydroxy-3-methylbutanoate

To a stirred solution of (*S*)-2-(9*H*-fluoren-9-ylmethoxycarbonylamino)-2-methyl-succinic acid 4-*tert*-butyl ester (**32**, 2.00 g, 4.72 mmol, 1.00 eq.), *N*-methylmorpholine (1.03 mL, 9.44 mmol, 2.00 eq.) in DCM (40 mL) at 0 °C, was added isobutyl chloroformate (1.22 mL, 9.44 mmol, 2.00 eq.) and the solution was stirred at 0 °C for 1 h. Solid sodium borohydride (534 mg, 14.2 mol, 3.00 eq.) was added and the reaction mixture was stirred at 0 °C for 1 h and at r.t. overnight. The reaction mixture was washed with water (3 $\times$ 5 mL), dried over MgSO₄ and concentrated to dryness to afford (*S*)-2-(((9*H*-fluoren-9-yl)methoxy)carbonyl)amino)-4-(*tert*-butoxy)-2-methyl-4-oxo-butanoic acid (1.90 g, 98%) as a white solid: LCMS (t_R = 1.25 min, purity = 99%), MS ESI⁺ m/z 434 (M+Na)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.95–7.84 (m, 1H), 7.73 (d, J = 7.5 Hz, 1H), 7.42 (td, J = 7.5, 1.2 Hz, 1H), 7.33 (tt, J = 7.5, 1.1 Hz, 1H), 6.84 (br s, 1H), 4.79 (s, 1H), 4.21 (d, J = 4.6 Hz, 2H), 3.76 (m, 2H), 2.90–2.68 (m, 1H), 2.51 (m, 1H), 1.36 (s, 9H), 1.23 (s, 3H).

4.5.3. *tert*-Butyl (*S*)-3-amino-4-hydroxy-3-methylbutanoate (**33**)

To a stirred solution of (*S*)-3-(9*H*-fluoren-9-ylmethoxycarbonylamino)-4-hydroxy-3-methyl-butanoic acid *tert*-butyl ester (1.50 g, 3.65 mmol, 1.00 eq.) in MeCN (15.0 mL) at r.t., was added pyrrolidine (60.2 μ L, 0.73 mmol, 0.20 eq.). The reaction mixture was stirred at r.t. for 24 h and concentrated to dryness. The residue was suspended in toluene and concentrated to dryness to afford *tert*-butyl (*S*)-3-amino-4-hydroxy-3-methylbutanoate (690 mg, quant.) as a pale yellow gum that was used without further purification: LCMS (t_R = 1.25 min, purity = 99%), ESI⁺ m/z 134 (M-C₄H₉+H)⁺.

4.5.4. *tert*-Butyl (3*S*)-4-hydroxy-3-methyl-3-(2-(3-methyl-2,6-dioxo-5-(4-(quinoxalin-2-ylamino)benzamido)-3,6-dihydropyrimidin-1(2*H*)-yl)propanamido)butanoate (**35**)

To a stirred solution of 2-{3-methyl-2,6-dioxo-5-[4-(quinoxalin-2-ylamino)-benzoylamino]-3,6-dihydro-2*H*-pyrimidin-1-yl]-propionic acid (**34**, 120 mg, 0.26 mmol, 1.00 eq.) and *N*-methylmorpholine (34.4 μ L, 0.31 mmol, 1.20 eq.) in DMF (2.40 mL) at r.t., was added HATU (119 mg, 0.31 mmol, 1.20 eq.) and the reaction mixture was stirred for 1 h 30 at r.t. then *tert*-butyl (*S*)-3-amino-4-hydroxy-3-methylbutanoate (**33**, 98.7 mg, 0.52 mmol, 2.00 eq.) was added and the reaction mixture was heated at 80 °C for 4 h and left to stir at r.t. for 48 h. The reaction mixture was partitioned between EtOAc (50 mL) and water (5 mL). The organic phase was retained and the aqueous phases washed with EtOAc (3 $\times$ 10 mL). The organic phases were combined, washed with water (4 $\times$ 10 mL), dried over MgSO₄ and concentrated to dryness. The residue was purified by flash chromatography (silica gel, gradient of 0–100% EtOAc in heptane) to afford *tert*-butyl (3*S*)-4-hydroxy-3-methyl-3-(2-(3-methyl-2,6-dioxo-5-(4-(quinoxalin-2-ylamino)benzamido)-3,6-dihydropyrimidin-1(2*H*)-yl)propanamido)butanoate (**35**, 100 mg, 45%) as a yellow solid as a mixture of diastereoisomers: LCMS (t_R = 1.19 min, purity = 74%), ESI⁺ m/z 576.2 (M-C₄H₉+H)⁺, 632.4 (M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.29 (s, 1H), 9.15 (d, J = 6.3 Hz, 1H), 8.63 (s, 1H), 8.35 (d, J = 10.3 Hz, 1H), 8.13 (d, J = 8.7 Hz, 2H), 8.02–7.94 (m, 3H), 7.91 (dd, J = 8.1, 1.5 Hz, 1H), 7.82 (dd, J = 8.4, 1.3 Hz, 1H), 7.71 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.54 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 6.99 (d, J = 21.4 Hz, 1H), 5.28 (m, 1H), 4.72 (t, J = 6.1 Hz, 0.5H), 4.59 (t, J = 6.1 Hz, 0.5H), 3.52 (m, 2H), 3.42–3.34 (d, J = 1.9 Hz, 3H), 2.67–2.55 (m, 1H), 2.46–2.23 (m, 1H), 1.46 (overlapping d, 3H), 1.40 (s, 9H), 1.26 (s, 3H).

4.5.5. *tert*-Butyl (3*S*)-4-hydroxy-3-methyl-3-(2-(3-methyl-2,6-dioxo-5-(4-(quinoxalin-2-ylamino)benzamido)-3,6-dihydropyrimidin-1(2*H*)-yl)propanamido)butanoate

To a stirred solution of *tert*-butyl (3*S*)-4-hydroxy-3-methyl-3-(2-(3-methyl-2,6-dioxo-5-(4-(quinoxalin-2-ylamino)benzamido)-3,6-dihydropyrimidin-1(2*H*)-yl)propanamido)butanoate (**35**, 100 mg, 0.11 mmol, 1.00 eq.) in DCM (1.40 mL) at 0 °C, was added Dess-Martin periodinane (1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1*H*)-one) (56.4 mg, 0.13 mmol, 1.20 eq.) and the reaction mixture was stirred overnight at r.t. The reaction mixture was diluted with DCM (20 mL), washed with 10% w/v NaHSO₄ (aq), dried over MgSO₄ and concentrated to dryness to afford *tert*-butyl (3*S*)-4-hydroxy-3-methyl-3-(2-(3-methyl-2,6-dioxo-5-(4-(quinoxalin-2-ylamino)benzamido)-3,6-dihydropyrimidin-1(2*H*)-yl)propanamido)butanoate (100 mg, quant.) as a complex mixture of diastereoisomers: LCMS (t_R = 1.22 min, purity = 96%), MS ESI⁺ m/z 630.4 (M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.30 (s, 1H), 9.28 (d, J = 16.0 Hz, 1H), 9.13 (d, J = 27.6 Hz, 1H), 8.63 (s, 1H), 8.36 (d, J = 3.9 Hz, 1H), 8.26 (d, J = 5.5 Hz, 1H), 8.18–7.95 (m, 3H), 7.94–7.85 (m, 4H), 7.85–7.76 (m, 4H), 7.71 (ddd, J = 8.4, 7.0, 1.6 Hz, 2H), 7.60–7.47 (m, 2H), 5.31 (m, 1H), 3.40 (d, J = 3.5 Hz, 3H), 2.81–2.59 (m, 2H), 1.47 (overlapping d, 3H), 1.40 (overlapping s, 9H), 1.28–1.22 (overlapping s, 3H).

4.5.6. *N*-(3-(1-(((3*S*)-2-Hydroxy-3-methyl-5-oxotetrahydro-furan-3-yl)amino)-1-oxopropan-2-yl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4-(quinoxalin-2-ylamino)benzamide (**36**)

To a stirred solution of *tert*-butyl (3*S*)-4-hydroxy-3-methyl-3-(2-(3-methyl-2,6-dioxo-5-(4-(quinoxalin-2-ylamino)benzamido)-3,6-dihydropyrimidin-1(2*H*)-yl)propanamido)butanoate (100 mg, 0.11 mmol, 1.00 eq.) in DCM (700 μ L) at r.t., was added TFA (60 μ L, 0.78 mmol, 7.00 eq.) and the reaction mixture is stirred at r.t. for 1 h. The reaction mixture was concentrated and the residue was purified by flash chromatography (silica gel, gradient of 0–5% MeOH in DCM) to afford *N*-(3-(1-(((3*S*)-2-Hydroxy-3-methyl-5-oxotetrahydrofuran-3-yl)amino)-1-oxopropan-2-yl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4-(quinoxalin-2-ylamino)benzamide (**35**, 25.0 mg, 36%) as a beige solid: LCMS (t_R = 0.97 min, purity = 96%), ESI⁺ m/z 574.23 (M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.36 (s, 1H), 9.16 (s, 1H), 8.64 (s, 1H), 8.34 (d, J = 9.4 Hz, 1H), 8.14 (d, J = 8.6 Hz, 2H), 7.99 (d, J = 8.6 Hz, 2H), 7.92 (d, J = 8.0 Hz, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.71 (t, J = 7.7 Hz, 1H), 7.54 (t, J = 7.7 Hz, 1H), 5.28 (br m, 1H), 3.38 (d, J = 3.7 Hz, 3H), 2.52–2.49 (hidden m, 2H), 1.45 (br s, 3H), 1.31 (br s, 3H).

4.6. *N*-(3-(1-(((3*R*)-2-hydroxy-5-oxotetrahydrofuran-3-yl)-carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)benzamide (**28**) was prepared in 6 steps

4.6.1. (*R*)-2-(((Allyloxy)carbonyl)amino)-4-(*tert*-butoxy)-4-oxo-butanoic acid

To a cooled (4 °C) solution of *D*-aspartic acid 4-*tert*-butyl ester (15.0 g, 78.3 mmol) in THF/H₂O (50 mL/150 mL) were added sodium bicarbonate (26.6 g, 317.1 mmol) and allyl chloroformate (15.17 mL, 57 g, 142.7 mmol). After 3 h of stirring at room temperature, the medium was extracted with EtOAc (three times). The aqueous layer was acidified with aqueous HCl (6 N) until obtaining pH 2. The aqueous layer was extracted (EtOAc, three times). The combined organic layer was dried over sodium sulphate, filtered and concentrated in vacuo to afford the title compound (18.7 g, 87%, as colorless oil): LCMS ESI[−] m/z 272.4 (M-H)[−]; ¹H NMR (CDCl₃, 500 MHz) δ 5.96–5.87 (m, 1H), 5.74 (br d, J = 8.5 Hz, 1H), 5.31 (m, 1H), 5.22 (m, 1H), 4.65–4.55 (m, 3H), 2.97 (dd, J = 17.0 Hz and 4.0 Hz, 1H), 2.76 (dd, J = 17.0 Hz and 5.0 Hz, 1H), 1.44 (s, 9H).

4.6.2. *tert*-Butyl (*R*)-3-(((allyloxy)carbonyl)amino)-4-(methoxy(methyl)amino)-4-oxo-butanoate

To a cooled solution of (*R*)-2-(((allyloxy)carbonyl)amino)-4-(*tert*-butoxy)-4-oxobutanoic acid (18.7 g, 68.7 mmol) in DCM (390 mL) were added *N,O*-dimethylhydroxylamine hydrochloride (8.00 g, 82.4 mmol), 4-methylmorpholine (9.07 mL, 82.4 mmol) and 1,(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (15.8 g, 82.4 mmol). After 3 h of stirring at room temperature, the medium was washed with aqueous HCl (1 N, two times), with brine, dried over sodium sulphate, filtered and concentrated in vacuo. Purification of the residue by chromatography on silica gel (cyclohexane-EtOAc, gradient of 9/1 to 7/3) afforded the title compound (15.3 g, 71%, as yellow oil): LCMS ESI⁺ m/z 317.3 (M+H)⁺; ¹H NMR (CDCl₃, 500 MHz) δ 5.93–5.85 (m, 1H), 5.59 (br d, J = 8.5 Hz, 1H), 5.30 (m, 1H), 5.19 (m, 1H), 5.00 (m, 1H), 4.56 (m, 2H), 3.78 (s, 3H), 3.21 (s, 3H), 2.70 (dd, J = 15.0 Hz and 5.5 Hz, 1H), 2.54 (dd, J = 15.0 Hz and 6.5 Hz, 1H), 1.43 (s, 9H).

4.6.3. *tert*-Butyl (*R*)-3-(((allyloxy)carbonyl)amino)-4-oxo-butanoate

A solution of lithium aluminium hydride (2 N in THF, 8.22 mL, 16.4 mmol) was added dropwise to a cooled (−78 °C) solution of

tert-butyl (*R*)-3-(((allyloxy)carbonyl)amino)-4-(methoxy(methyl)amino)-4-oxobutanoate (8.0 g, 25.3 mmol) in anhydrous THF (107 mL). The mixture was stirred at −78 °C for 3 h, then aqueous HCl (1 N) was slowly added to the medium, and the temperature was allowed to warm to 0 °C. The mixture was diluted with EtOAc. The aqueous layer was extracted (EtOAc). The combined organic layer was washed with aqueous HCl (1 N), with brine, dried over sodium sulphate, filtered and concentrated in vacuo to afford the title compound (6.65 g, quantitative, as pale yellow oil): ¹H NMR (CDCl₃, 500 MHz) δ 9.66 (s, 1H), 5.83 (br d, 1H), 5.99–5.82 (m, 1H), 5.33 (m, 1H), 5.24 (m, 1H), 4.61 (m, 2H), 4.36 (m, 1H), 2.96 (dd, J = 17.2 Hz and 4.5 Hz, 1H), 2.76 (dd, J = 17.2 Hz and 5.1 Hz, 1H), 1.43 (s, 9H).

4.6.4. *tert*-Butyl (*R*)-3-(((allyloxy)carbonyl)amino)-4,4-diethoxy-butanoate

To a freshly prepared solution of *tert*-butyl (*R*)-3-(((allyloxy)carbonyl)amino)-4-oxobutanoate (6.65 g, 25.8 mmol) in absolute ethanol (28 mL) were added, under Argon atmosphere, triethyl orthoformate (12.9 mL, 77.5 mmol), *p*-toluenesulfonic acid (133 mg, 0.77 mmol) and 3 Å molecular sieves. After stirring at room temperature for 3 days, the mixture was filtered over a pad of celite and rinsed with EtOH. The filtrate was concentrated under reduced pressure. Purification of the residue by flash chromatography on silica gel (cyclohexane-EtOAc, 9/1) afforded the title compound (4.87 g, 50%) as colorless oil: ¹H NMR (CDCl₃, 400 MHz) δ 5.83–6.00 (m, 1H), 5.30 (d, J = 17.4 Hz, 1H), 5.23 (br d, J = 8.5 Hz, 1H), 5.21 (m, 1H), 4.56 (m, 2H), 4.49 (m, 1H), 4.22–4.11 (m, 1H), 3.65–3.78 (m, 2H), 3.48–3.61 (m, 2H), 2.56 (dd, J = 15.6 Hz and 5.7 Hz, 1H), 2.45 (dd, J = 15.6 Hz and 7.2 Hz, 1H), 1.44 (s, 9H), 1.21 (m, 6H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 170.12, 155.44, 133.78, 116.66, 102.57, 79.66, 64.16, 63.39, 62.22, 50.44, 36.09, 27.69, 15.15; [α]_D²⁰ = +17.8° (c = 18 g/L, MeCN).

4.6.5. *N*-(3-(1-(((3*R*)-2-ethoxy-5-oxotetrahydrofuran-3-yl)-carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)benzamide

First Step: To a stirred solution of 1-[3-isopropyl-5-[2-methyl-4-(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-3,6-dihydro-2*H*-pyrimidin-1-yl]-cyclopropanecarboxylic acid, (283 mg, 0.55 mmol, 1.00 eq.) and *N*-methyl morpholine (72.9 μ L, 0.66 mmol, 1.20 eq.) in a mixture of DCM (1.27 mL) and DMF (1.27 mL), HATU (252 mg, 0.66 mmol, 1.20 eq.) was added and the reaction mixture was stirred at r.t. for 45 min.

Second Step: In parallel, a solution of ((*R*)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-carbamic acid allyl ester, (190 mg, 0.83 mmol, 1.40 eq.) and 1,3-dimethylbarbituric acid (129 mg, 0.83 mmol, 1.50 eq.) in a mixture of DCM (0.89 mL) and DMF (0.63 mL) at r.t. was degassed and purged with nitrogen then tetrakis(triphenylphosphine)palladium(0) (25.5 mg, 0.02 mmol, 0.04 eq.) was added. The reaction mixture was stirred at room temperature for 1 h.

Third step: The product, (4*S*)-4-amino-5-ethoxydihydrofuran-2(3*H*)-one, from the Alloc deprotection step was added to the pre-activated ester for the first step and the reaction mixture was stirred at room temperature overnight. The reaction mixture was treated with a saturated solution of NaHCO₃(aq) and the product extracted with EtOAc (2 × 20 mL). The organic phases were combined and washed with water (3 × 5 mL), dried over MgSO₄ and concentrated to dryness. The crude product was purified by flash chromatography (silica gel, gradient of 0–5% MeOH in DCM) to afford *N*-(3-[1-((*R*)-2-ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-cyclopropyl]-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)-benzamide (1.80 g, quant.) as an orange solid (mixture of diastereoisomers): LCMS (t_R = 1.27 min,

purity = 100%), ESI⁺ *m/z* 640.20 (M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.96–8.75 (overlapping s, 1H), 8.70 (s, 1H), 8.43 (s, 1H), 8.23 (d, *J* = 7.1 Hz, 0.5H), 8.05–7.91 (m, 0.5H), 7.91–7.69 (m, 3H), 7.67–7.53 (m, 3H), 7.52–7.39 (m, 2H), 7.37–7.27 (m, 2H), 7.12–7.00 (m, 2H), 5.50 (d, *J* = 5.3 Hz, 0.5H), 5.22 (d, *J* = 6.0 Hz, 0.5H), 4.90–4.51 (m, 1H), 4.04 (overlapping signals, 0.5H), 3.84–3.47 (overlapping signals, 2H), 2.99 (m, 0.5H), 2.68–2.53 (m, 1H), 2.44 (s, 3H), 2.39–2.28 (m, 1H), 1.83–1.53 (m, 2H), 1.48–1.24 (m, 6H), 1.23–1.06 (m, 5H).

4.6.6. *N*-(3-(1-(((3*R*)-2-Hydroxy-5-oxotetrahydrofuran-3-yl)carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)benzamide (28)

To a stirred solution of *N*-[3-[1-((*S*)-2-ethoxy-5-oxo-tetrahydrofuran-3-ylcarbamoyl)-cyclopropyl]-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl]-2-methyl-4-(naphthalen-2-ylamino)-benzamide (280 mg, 0.44 mmol, 1.00 eq.) in MeCN (5.60 mL) was added HCl (aq) (2M, 2.19 mL, 4.38 mmol, 10.0 eq.) and the reaction mixture was stirred at room temperature for 5 h. The volatiles were eliminated under a flow of nitrogen and the residue was treated with a saturated aqueous solution of NaHCO₃ (pH 8) then diluted with EtOAc. The organic phase was discarded and the pH of the aqueous phase was adjusted to 5 with AcOH. The product was extracted in EtOAc (3 × 5 mL), the organic phases were combined, dried over MgSO₄ and concentrated to dryness. The resulting beige solid was crystallised from a mixture of EtOAc/toluene and the solid was recuperated by filtration and dried to a constant weight un a vacuum oven at 40 °C to afford *N*-(3-(1-(((3*R*)-2-hydroxy-5-oxotetrahydrofuran-3-yl)carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)benzamide (1.07 g, 65%) as an off-white solid: LCMS (*t*_R = 1.19 min, purity = 99%), ESI⁺ *m/z* 612.36 (M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.96–8.83 (m, 1H), 8.71 (s, 1H), 8.42 (s, 1H), 8.21 (br s, 1H), 7.87–7.73 (m, 3H), 7.58 (d, *J* = 2.3 Hz, 1H), 7.50 (d, *J* = 8.4 Hz, 1H), 7.43 (ddd, *J* = 8.2, 6.8, 1.3 Hz, 1H), 7.36–7.27 (m, 2H), 7.07 (dd, *J* = 8.3, 2.3 Hz, 1H), 7.03 (d, *J* = 2.3 Hz, 1H), 5.41 (br s, 1H), 4.78 (m, 1H), 4.15 (s br, 1H), 2.93 (m, 1H), 2.44 (s, 3H), 2.32 (m, 1H), 1.65 (m, 2H), 1.32 (dd, *J* = 13.1, 6.7 Hz, 6H), 1.16 (m, 2H).

4.7. *N*-(3-(1-(((4*R*)-2-hydroxy-6-oxotetrahydro-2*H*-pyran-4-yl)carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)-benzamide (37) was prepared in 7 steps

4.7.1. *tert*-Butyl (R)-3-(((9*H*-fluoren-9-yl)methoxy)-carbonyl)-amino)-5-(methoxy(methyl)amino)-5-oxopentanoate

To a cooled solution of Fmoc-β-homoaspartic acid(O-*t*Bu) (20.0 g, 47.0 mmol) in DCM (268 mL) were added *N*,*O*-dimethylhydroxylamine hydrochloride (5.5 g, 56.4 mmol), 4-methylmorpholine (6.2 mL, 56.4 mmol) and 1,(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (10.8 g, 56.4 mmol). After 2 h of stirring at room temperature, the medium was washed with aqueous HCl (1 N, two times), with brine, dried over sodium sulphate, filtered and concentrated in vacuo. Purification of the residue by chromatography on silica gel (cyclohexane-EtOAc, gradient of 8/2 to 6/4) afforded the title compound (22.6 g, quantitative): LCMS (*t*_R = 3.75 min, purity = 100%), ESI⁺ *m/z* 469.2 (M+H)⁺; ¹H NMR (CDCl₃) δ 7.75 (d, *J* = 7.5 Hz, 2H), 7.57–7.60 (m, 2H), 7.39 (t, *J* = 7.5 Hz, 2H), 7.30 (td, *J* = 7.5 Hz and 1.0 Hz, 2H), 5.95 (d, *J* = 7.8 Hz, 1H), 4.40–4.35 (m, 3H), 4.21 (m, 1H), 3.70 (s, 3H), 3.21 (s, 3H), 2.97–2.94 (m, 1H), 2.73–2.64 (m, 2H), 2.61 (dd, *J* = 15.7 Hz and 7.0 Hz, 1H), 1.44 (s, 9H).

4.7.2. *tert*-Butyl (R)-3-amino-5-(methoxy(methyl)amino)-5-oxopentanoate

To a cooled (0 °C) solution of *tert*-butyl (R)-3-(((9*H*-fluoren-9-

yl)methoxy)carbonyl)amino)-5-(methoxy(methyl)amino)-5-oxopentanoate (22.6 g, 48.2 mmol) in DCM (377 mL) was added dropwise DBU (7.92 mL, 5.0 mmol). After 1 h 30 of stirring at room temperature, the medium was concentrated under vacuum. Purification of the residue by chromatography on silica gel (DCM - MeOH/NH₃ (7 N), gradient of 97/3 to 95/5) afforded the title compound (8.11 g, 68%, as yellow oil): ¹H NMR (CDCl₃) δ 3.70–3.63 (m, 1H), 3.68 (s, 3H), 3.17 (s, 3H), 2.64–2.60 (m, 1H), 2.57–2.52 (m, 1H), 2.45 (dd, *J* = 15.8 Hz and 5.0 Hz, 1H), 2.39 (dd, *J* = 15.8 Hz and 8.0 Hz, 1H), 1.45 (s, 9H).

4.7.3. *tert*-Butyl (R)-3-(((allyloxy)carbonyl)amino)-5-(methoxy-methyl)amino)-5-oxo-pentanoate

To a cooled (4 °C) solution of *tert*-butyl (R)-3-amino-5-(methoxy(methyl)amino)-5-oxopentanoate (8.11 g, 32.9 mmol) in THF/H₂O (20 mL/60 mL) were added sodium bicarbonate (41.1 g, 131.6 mmol) and allyl chloroformate (6.30 mL, 59.2 mmol). After 1 h 30 of stirring at room temperature, the medium was extracted with EtOAc (3 × 20 mL). The combined organic layer was dried over sodium sulphate, filtered and concentrated in vacuo. Purification of the residue by chromatography on silica gel (cyclohexane-EtOAc, gradient of 8/2 to 6/4) afforded the title compound (9.58 g, 88%) as a colorless oil: ¹H NMR (CDCl₃) δ 5.93–5.83 (m, 2H), 5.29 (d, *J* = 17.3 Hz, 1H), 5.18 (m, 1H), 4.54 (m, 2H), 4.32–4.36 (m, 1H), 3.67 (s, 3H), 3.17 (s, 3H), 2.91–2.86 (m, 1H), 2.72–2.65 (m, 2H), 2.59 (dd, *J* = 15.8 Hz and 6.9 Hz, 1H), 1.44 (s, 9H).

4.7.4. *tert*-Butyl (R)-3-(((allyloxy)carbonyl)amino)-5-oxo-pentanoate

A solution of lithium aluminium hydride (2 N in THF, 5.90 mL, 11.8 mmol) was added dropwise to a cooled (–78 °C) solution of *tert*-butyl (R)-3-(((allyloxy)carbonyl)amino)-5-(methoxy-(methyl)amino)-5-oxopentanoate (6.0 g, 18.1 mmol) in anhydrous THF (80 mL). The mixture was stirred at –78 °C for 2 h 30, then aqueous HCl (1 N) was slowly added to the medium, and the temperature was allowed to warm to 0 °C. The mixture was diluted with EtOAc. The aqueous layer was extracted (EtOAc, two times). The combined organic layer was washed with aqueous HCl (1 N), with brine, dried over sodium sulphate, filtered and concentrated in vacuo to afford the title compound (4.7 g, 95%, as pale yellow oil): ¹H NMR (CDCl₃) δ 9.75 (t, *J* = 1.4 Hz, 1H), 5.94–5.86 (m, 1H), 5.48 (br s, 1H), 5.29 (m, 1H), 5.20 (m, 1H), 4.54 (d, *J* = 4.9 Hz, 2H), 4.37–4.40 (m, 1H), 2.83 (dd, *J* = 17.5 Hz and 5.5 Hz, 1H), 2.74 (ddd, *J* = 17.5 Hz, 6.0 Hz and 1.4 Hz, 1H), 2.58 (d, *J* = 5.8 Hz, 2H), 1.44 (s, 9H).

4.7.5. *tert*-Butyl (R)-3-(((allyloxy)carbonyl)amino)-5,5-diethoxy-pentanoate

To a freshly prepared solution of *tert*-butyl (R)-3-(((allyloxy)carbonyl)amino)-5-oxopentanoate (4.7 g, 17.3 mmol) in absolute ethanol (20 mL) were added, under Argon atmosphere, triethyl orthoformate (11.5 mL, 69.3 mmol), *p*-toluenesulfonic acid (90 mg, 0.52 mmol) and 3 Å molecular sieves. After stirring at room temperature overnight, the mixture was filtered over a pad of Celite and rinsed with EtOH. The filtrate was concentrated under reduced pressure and co-evaporated with toluene (three times). Purification of the residue by flash chromatography on silica gel (cyclohexane-EtOAc, gradient of 9/1 to 8/2) afforded the title compound (4.85 g, 81%, as pale yellow oil): ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.13 (d, *J* = 8.8 Hz, 1H), 5.92–5.85 (m, 1H), 5.27–5.24 (m, 1H), 5.17–5.14 (m, 1H), 4.47–4.44 (m, 3H), 3.90–3.84 (m, 1H), 3.59–3.50 (m, 2H), 3.43–3.73 (m, 2H), 2.36–2.28 (m, 2H), 1.65 (m, 2H), 1.37 (s, 9H), 1.09 (m, 6H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 169.97, 155.13, 133.83, 116.63, 100.06, 79.73, 64.09, 61.11, 60.48, 45.22, 41.12, 38.26, 27.67, 15.29; [α]_D²⁰ = +13.4° (c = 10 g/L, EtOH). HRMS: (M+H)⁺ calculated for C₁₇H₃₁NO₆ 345.2151; found 368.2083 (M+Na)⁺, 713.4276

(2M+Na)⁺, 244.1206 cyclized warhead eg., (M(-OEt, -C₄H₉)+H)⁺.

4.7.6. *tert*-Butyl (R)-5,5-Diethoxy-3-(1-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)-benzamido)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)cyclopropane-1-carboxamido)-pentanoate

Step 1: To a stirred solution 1-[3-isopropyl-5-[2-methyl-4-(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-cyclopropanecarboxylic acid (100 mg, 0.20 mmol, 1.00 eq.) and *N*-methylmorpholine (25.7 μ L, 0.23 mmol, 1.20 eq.) in a mixture of DCM (700 μ L) and DMF (1.00 mL), was added HATU (89.0 mg, 0.23 mmol, 1.20 eq.) and the reaction mixture was stirred at room temperature for 30 min.

Step 2: In a separate flask, a solution of (R)-3-allyloxy-carbonylamino-5,5-diethoxy-pentanoic acid *tert*-butyl ester (101 mg, 0.29 mmol, 1.50 eq.) and 1,3-dimethylbarbituric acid (45.7 mg, 0.29 mmol, 1.50 eq.) in a mixture of DCM (700 μ L) and DMF (500 μ L) was degassed and purged with nitrogen then tetrakis(triphenylphosphine)palladium(0) (9.02 mg, 0.01 mmol, 0.04 eq.) was added. The reaction mixture was stirred at r.t. for 30 min.

Step 3: The solution from the Alloc deprotection containing *tert*-butyl (R)-3-amino-5,5-diethoxypentanoate was added dropwise to the activated ester formed in Step 1 and the resulting solution was stirred for 2 h at r.t. The reaction mixture was diluted with EtOAc (30 mL) and washed with a saturated aqueous solution of NaHCO₃. The aqueous phase was washed with EtOAc (2 $\times$ 10 mL). The organic phases were combined, dried over MgSO₄ and concentrated to dryness. The residue was purified by flash chromatography (silica gel, gradient of 0–100% EtOAc in heptane) to afford *tert*-butyl (R)-5,5-diethoxy-3-(1-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)-benzamido)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)cyclopropane-1-carboxamido)-pentanoate (140 mg, 95%) as a yellow solid: LCMS (*t*_R = 1.44 min, purity = 100%), MS ES[−] *m/z* 754.48 (M-H)[−]; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.83 (d, *J* = 6.3 Hz, 1H), 8.72 (s, 1H), 8.42 (d, *J* = 6.3 Hz, 1H), 7.89–7.71 (m, 3H), 7.69–7.55 (m, 2H), 7.53–7.38 (m, 2H), 7.38–7.28 (m, 2H), 7.13–6.99 (m, 2H), 4.77 (p, *J* = 6.7 Hz, 1H), 4.46 (dd, *J* = 8.1, 3.1 Hz, 1H), 3.49 (overlapping m, 4H), 2.65–2.53 (m, 1H), 2.44 (s, 3H), 2.39–2.17 (m, 1H), 1.81–1.50 (m, 2H), 1.47–1.18 (overlapping signals, 17H), 1.10 (m, 6H).

4.7.7. *N*-(3-(1-(((4S)-2-hydroxy-6-oxotetrahydro-2H-pyran-4-yl)carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)-benzamide (37)

To a stirred solution of (R)-5,5-diethoxy-3-[(1-[3-isopropyl-5-[2-methyl-4-(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-cyclopropanecarbonyl)-amino]-pentanoic acid *tert*-butyl ester (200 mg, 0.26 mmol, 1.00 eq.) in DCM (6.00 mL) at 0 °C, was added TFA (6.00 mL, 78.4 mmol) dropwise over 2 min. The reaction mixture was stirred at r.t. for 2 h. The reaction mixture was carefully added to a mixture of ice and a saturated solution of NaHCO₃ (aq). The pH of the reaction mixture was brought up to 8 with 1M NaOH (aq) then lowered to 5 with AcOH and the product extracted with DCM (2 $\times$ 10 mL). The organic extracts were combined, washed with water (2 $\times$ 2 mL), dried over MgSO₄ and concentrated to dryness. The residue was purified by flash chromatography (silica gel, gradient of 2–10% MeOH in DCM) to afford a yellow solid. The solid was triturated with heptane and stirred overnight, recuperated by filtration and dried to a constant weight to afford *N*-(3-(1-(((4S)-2-hydroxy-6-oxotetrahydro-2H-pyran-4-yl)carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)-benzamide (134 mg, 80%) as an off-white solid: LCMS (*t*_R = 6.57 min, purity = 98.4%), ESI⁺ *m/z* 626.25 (M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.52 (s, 1H), 8.84 (s, 1H), 8.72 (s, 1H), 8.41 (s,

1H), 7.99 (s, 1H), 7.71–7.88 (m, 3H), 7.58 (d, *J* = 2.4 Hz, 1H), 7.50 (d, *J* = 8.6 Hz, 1H), 7.43 (ddd, *J* = 8.2, 6.8, 1.3 Hz, 1H), 7.26–7.37 (m, 2H), 6.94–7.03 (m, 2H), 4.76 (s, 1H), 4.46 (s, 1H), 2.30–2.50 (m, 2H), 2.44 (s, 3H), 2.38 (d, *J* = 10.9 Hz, 2H), 1.61 (m, 2H), 1.28–1.38 (m, 6H), 1.11 (s, 2H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 169.04, 167.23, 160.07, 149.74, 148.66, 145.39, 140.14, 138.32, 135.06, 134.26, 129.48, 128.99, 128.72, 128.33, 127.51, 126.51, 126.40, 126.10, 123.46, 120.60, 118.24, 113.92, 112.85, 111.52, 48.08, 42.61, 37.37, 31.30, 28.41, 22.14, 20.59, 14.00; HRMS (M+H)⁺ calculated for C₃₄H₃₅N₅O₇ 626.2536; found 626.2605.

4.8. *N*-(3-(1-(((4S)-2-Hydroxy-6-oxotetrahydro-2H-pyran-4-yl)carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)-benzamide (38) was prepared in 7 steps

4.8.1. *tert*-Butyl (S)-3-(((9H-fluoren-9-yl)methoxy)-carbonyl)-amino)-5-(methoxy(methyl)amino)-5-oxopentanoate

To a cooled solution of (S)-3-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(*tert*-butoxy)-5-oxopentanoic acid (5.0 g, 11.7 mmol) in DCM (67 mL) were added *N*,*O*-dimethylhydroxylamine hydrochloride (1.38 g, 14.1 mmol), 4-methylmorpholine (1.55 mL, 14.1 mmol) and 1,(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.70 g, 14.1 mmol). After 2 h 30 of stirring at room temperature, the medium was washed with aqueous HCl (1 N, three times), with saturated aqueous sodium bicarbonate, with brine, dried over sodium sulphate, filtered and concentrated in vacuo to afford the title compound (4.98 g, 90%) as a pale yellow paste: LCMS (*t*_R = 3.75 min, purity = 100%), ESI⁺ *m/z* 469.2 (M+H)⁺; ¹H NMR (CDCl₃) δ 7.75 (d, *J* = 7.5 Hz, 2H), 7.60–7.57 (m, 2H), 7.39 (t, *J* = 7.5 Hz, 2H), 7.30 (td, *J* = 7.5 Hz and 1.0 Hz, 2H), 5.95 (d, *J* = 7.8 Hz, 1H), 4.40–4.35 (m, 3H), 4.21 (m, 1H), 3.70 (s, 3H), 3.21 (s, 3H), 2.97–2.94 (m, 1H), 2.73–2.68 (m, 2H), 2.61 (dd, *J* = 15.7 Hz and 7.0 Hz, 1H), 1.44 (s, 9H).

4.8.2. *tert*-Butyl (S)-3-amino-5-(methoxy(methyl)amino)-5-oxopentanoate

To a solution of *tert*-butyl (S)-3-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(methoxy(methyl)amino)-5-oxopentanoate (4.95 g, 10.5 mmol) in DCM (80 mL) was added dropwise DBU (1.73 mL, 11.6 mmol). After 2 h 30 of stirring at room temperature, the medium was concentrated under vacuum. Purification of the residue by chromatography on silica gel (DCM - MeOH/NH₃ (7 N), 95/5) afforded the title compound (2.45 g, 75%) as a yellow oil; ¹H NMR (CDCl₃, 500 MHz) δ 3.63–3.68 (m, 1H), 3.68 (s, 3H), 3.17 (s, 3H), 2.64–2.60 (m, 1H), 2.57–2.52 (m, 1H), 2.45 (dd, *J* = 15.8 Hz and 5.0 Hz, 1H), 2.39 (dd, *J* = 15.8 Hz and 8.0 Hz, 1H), 1.45 (s, 9H).

4.8.3. *tert*-Butyl (S)-3-(((allyloxy)carbonyl)amino)-5-(methoxy(methyl)amino)-5-oxopentanoate

To a cooled (4 °C) solution of *tert*-butyl (S)-3-amino-5-(methoxy(methyl)amino)-5-oxopentanoate (2.45 g, 9.95 mmol) in THF/H₂O (6 mL/18 mL) were added sodium bicarbonate (3.34 g, 39.79 mmol) and allyl chloroformate (1.90 mL, 17.9 mmol). After 2 h 30 of stirring at room temperature, the medium was extracted with EtOAc (three times). The combined organic layer was dried over sodium sulphate, filtered and concentrated in vacuo. Purification of the residue by chromatography on silica gel (cyclohexane-EtOAc, gradient of 8/2 to 4/6) afforded the title compound (1.32 g, 40%) as a colorless oil: LCMS (*t*_R = 3.00 min, purity = 100%), ESI⁺ *m/z* 331.1 (M+H)⁺; ¹H NMR (CDCl₃) δ 5.83–5.93 (m, 2H), 5.29 (d, *J* = 17.3 Hz, 1H), 5.18 (m, 1H), 4.54 (m, 2H), 4.36–4.32 (m, 1H), 3.67 (s, 3H), 3.17 (s, 3H), 2.91–2.86 (m, 1H), 2.72–2.65 (m, 2H), 2.59 (dd, *J* = 15.8 Hz and 6.9 Hz, 1H), 1.44 (s, 9H).

4.8.4. *tert*-Butyl (S)-3-(((allyloxy)carbonyl)amino)-5-oxopentanoate

A solution of lithium aluminium hydride (2 N in THF, 1.28 mL, 2.56 mmol) was added dropwise to a cooled (-78°C) solution of *tert*-butyl (S)-3-(((allyloxy)carbonyl)amino)-5-(methoxy-(methyl)amino)-5-oxopentanoate (1.30 g, 3.93 mmol) in anhydrous THF (16 mL). The mixture was stirred at -78°C for 3 h, then aqueous HCl (1 N) was slowly added to the medium, and the temperature was allowed to warm to 0°C . The mixture was diluted with EtOAc. The aqueous layer was extracted (EtOAc, two times). The combined organic layer was washed with aqueous HCl (1 N), with brine, dried over sodium sulphate, filtered and concentrated in vacuo to afford the title compound (1.05 g, 98%) as a pale yellow oil: ^1H NMR (CDCl_3) δ 9.75 (t, $J = 1.4$ Hz, 1H), 5.86–5.94 (m, 1H), 5.48 (br s, 1H), 5.29 (m, 1H), 5.20 (m, 1H), 4.54 (d, $J = 4.9$ Hz, 2H), 4.40–4.37 (m, 1H), 2.83 (dd, $J = 17.5$ Hz and 5.5 Hz, 1H), 2.74 (ddd, $J = 17.5$ Hz, 6.0 Hz and 1.4 Hz, 1H), 2.58 (d, $J = 5.8$ Hz, 2H), 1.44 (s, 9H).

4.8.5. *tert*-Butyl (S)-3-(((allyloxy)carbonyl)amino)-5,5-diethoxypentanoate

To a freshly prepared solution of *tert*-butyl (S)-3-(((allyloxy)carbonyl)amino)-5-oxopentanoate (1.05 g, 3.87 mmol) in absolute ethanol (3.5 mL) were added, under an argon atmosphere, triethyl orthoformate (1.61 mL, 9.68 mmol), *p*-toluenesulfonic acid (13 mg, 0.077 mmol) and 3 Å molecular sieves. After stirring at room temperature overnight, the mixture was filtered over a pad of celite and rinsed with EtOH. The filtrate was concentrated under reduced pressure and co-evaporated with toluene (three times). Purification of the residue by flash chromatography on silica gel (cyclohexane–EtOAc, gradient of 9/1 to 75/25) afforded the title compound (1.07 g, 80%) as a pale yellow oil; LCMS ($t_R = 3.53$ min, purity = 100%), $\text{ESI}^+ m/z$ 300.1 ($\text{M}(-\text{OEt})+\text{H}^+$); ^1H NMR ($\text{DMSO}-d_6$, 400 MHz) δ 7.13 (d, $J = 8.8$ Hz, 1H), 5.92–5.84 (m, 1H), 5.27–5.24 (m, 1H), 5.17–5.14 (m, 1H), 4.47–4.44 (m, 3H), 3.90–3.84 (m, 1H), 3.59–3.50 (m, 2H), 3.43–3.37 (m, 2H), 2.36–2.28 (m, 2H), 1.65 (m, 2H), 1.37 (s, 9H), 1.09 (m, 6H); ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 169.97, 155.13, 133.83, 116.63, 100.06, 79.73, 64.09, 61.11, 60.48, 45.22, 41.12, 38.26, 27.67, 15.29; $[\alpha]_D^{20} = -12.8^{\circ}$ ($c = 10$ g/L, EtOH); HRMS: ($\text{M}+\text{H}^+$) calculated for $\text{C}_{17}\text{H}_{31}\text{NO}_6$ 345.2151; found 368.2082 ($\text{M}+\text{Na}^+$), 713.4275 ($2\text{M}+\text{Na}^+$), 244.1205 cyclized warhead *eg.*, ($\text{M}(-\text{OEt}, -\text{C}_4\text{H}_9) + \text{H}^+$).

4.8.6. *tert*-Butyl (S)-5,5-diethoxy-3-(1-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)-benzamido)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)cyclopropane-1-carboxamido)-pentanoate

Step 1: To a stirred solution of 1-[3-Isopropyl-5-[2-methyl-4-(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-cyclopropanecarboxylic acid (100 mg, 0.20 mmol, 1.00 eq.) and *N*-methylmorpholine (25.7 μL , 0.23 mmol, 1.20 eq.) in a mixture of DCM (700 μL) and DMF (1.00 mL), was added HATU (89.0 mg, 0.23 mmol, 1.20 eq.) and the reaction mixture was stirred at room temperature for 30 min.

Step 2: In parallel, a stirred solution of (S)-3-allyloxycarbonylamino-5,5-diethoxy-pentanoic acid *tert*-butyl ester (101 mg, 0.29 mmol, 1.50 eq.) and 1,3-dimethylbarbituric acid (45.7 mg, 0.29 mmol, 1.50 eq.) in a mixture of DCM (700 μL) and DMF (500 μL) was degassed and purged with nitrogen then tetrakis(triphenylphosphine)palladium(0) (9.02 mg, 0.01 mmol, 0.04 eq.) was added. The reaction mixture was agitated for 30 min.

Step 3: The solution containing *tert*-butyl (S)-3-amino-5,5-diethoxypentanoate was added dropwise to the pre-activated ester for Step 1 and the resulting solution was stirred for 2 h at r.t. The reaction mixture was diluted with EtOAc (50 mL) and washed with a saturated aqueous solution of NaHCO_3 . The aqueous phase was washed with EtOAc (3×10 mL). The organic phases were

combined, dried over MgSO_4 and concentrated to dryness. The residue was purified by flash chromatography (silica gel, gradient of 0–100% EtOAc in heptane) to afford *tert*-butyl (S)-5,5-diethoxy-3-(1-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)-benzamido)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)cyclopropane-1-carboxamido)-pentanoate (141 mg, 96%) as a beige solid; LCMS ($t_R = 1.44$ min, purity = 100%), MS $\text{ESI}^- m/z$ 754.63 ($\text{M}-\text{H}^-$); ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.83 (d, $J = 6.4$ Hz, 1H), 8.72 (s, 1H), 8.42 (d, $J = 6.4$ Hz, 1H), 7.88–7.72 (m, 3H), 7.69–7.52 (m, 4H), 7.52–7.39 (m, 1H), 7.38–7.27 (m, 2H), 7.12–7.00 (m, 2H), 5.83–5.57 (m, 1H), 5.17–4.95 (m, 1H), 4.90–4.59 (m, 1H), 4.46 (m, 1H), 4.16 (overlapping m, 1H), 3.70–3.35 (overlapping m, 4H), 2.75–2.55 (m, 1H), 2.44 (s, 3H), 2.37–2.15 (m, 1H), 1.78–1.53 (m, 2H), 1.46–1.18 (overlapping m, 17H), 1.10 (m, 6H).

4.8.7. *N*-(3-(1-(((4S)-2-Hydroxy-6-oxotetrahydro-2H-pyran-4-yl)carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)benzamide (**38**)

To a stirred solution of *tert*-butyl (S)-5,5-diethoxy-3-(1-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)-benzamido)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)cyclopropane-1-carboxamido)-pentanoate (260 mg, 0.34 mmol, 1.00 eq.) in DCM (7.8 mL) was added TFA (7.8 mL) at 0°C . The reaction mixture is stirred at r.t. for 2 h. The reaction mixture was carefully added to a mixture of ice and a saturated solution of NaHCO_3 (aq). The pH of the reaction mixture was lowered to 5 with AcOH and the product extracted with DCM (2×5 mL). The organic extracts were combined, washed with water (2×2 mL), dried over MgSO_4 and concentrated to dryness. The residue was purified by flash chromatography (silica gel, gradient of 2–10% MeOH in DCM) to afford a yellow solid. The solid was triturated with heptane and stirred overnight, recuperated by filtration and dried to a constant weight to afford *N*-(3-(1-(((4S)-2-hydroxy-6-oxotetrahydro-2H-pyran-4-yl)carbamoyl)cyclopropyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)benzamide (129 mg, 59%) as a pale yellow solid; LCMS ($t_R = 5.96$ min, purity = 98%), MS $\text{ESI}^+ m/z$ 624.57 ($\text{M}-\text{H}^+$); ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.53 (s, 1H), 8.84 (s, 1H), 8.71 (s, 1H), 8.40 (s, 1H), 7.70–7.90 (m, 3H), 7.58 (d, $J = 2.3$ Hz, 1H), 7.50 (d, $J = 8.5$ Hz, 1H), 7.42 (d, $J = 7.4$ Hz, 1H), 7.24–7.38 (m, 2H), 6.94–7.13 (m, 2H), 4.76 (s, 1H), 4.42 (s, 1H), 2.40–2.50 (m, 2H), 2.44 (s, 3H), 2.32 (s, 2H), 1.69–1.81 (m, 2H), 1.32 (dd, $J = 11.0$, 6.7 Hz, 6H), 1.11 (s, 2H); ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 169.04, 167.23, 160.07, 149.74, 148.66, 145.39, 140.14, 138.32, 135.06, 134.26, 129.48, 128.99, 128.72, 128.33, 127.51, 126.51, 126.40, 126.10, 123.46, 120.60, 118.24, 113.92, 112.85, 111.52, 48.08, 42.61, 37.37, 31.30, 28.41, 22.14, 20.59, 14.00; HRMS: ($\text{M}+\text{H}^+$) calculated for $\text{C}_{34}\text{H}_{35}\text{N}_5\text{O}_7$ 626.2536; found, 626.2600.

4.9. *N*-(3-(1-(((3S)-2-Hydroxy-6-oxotetrahydro-2H-pyran-3-yl)amino)-1-oxopropan-2-yl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)benzamide (**39**) prepared in 6 steps

4.9.1. (S)-2-(((Allyloxy)carbonyl)amino)-5-(*tert*-butoxy)-5-oxopentanoic acid

To a cooled (4°C) solution of L-glutamic acid 4-*tert*-butyl ester (15.0 g, 73.8 mmol) in THF/ H_2O (45 mL/135 mL) were added sodium bicarbonate (24.8 g, 295.2 mmol) and allyl chloroformate (14.12 mL, 132.8 mmol). After 3 h of stirring at room temperature, the medium was acidified with aqueous HCl (6 N) until obtaining pH 2. The aqueous layer was extracted (EtOAc). The organic layer was dried over sodium sulphate, filtered and concentrated under reduced pressure. The residue was dissolved in saturated aqueous sodium bicarbonate. The aqueous layer was extracted (EtOAc). The organic

layer was washed with saturated aqueous sodium bicarbonate. The basic layers were combined, acidified with aqueous HCl (6 N) until obtaining pH 2 and extracted (EtOAc). The organic layer was dried over sodium sulphate, filtered and concentrated under vacuum to afford the title compound (19.7 g, 93%) as a colorless oil: ^1H NMR (CDCl_3 , 500 MHz) δ 5.95–5.87 (m, 1H), 4.58 (m, 2H), 5.49 (br d, $J = 7.5$ Hz, 1H), 5.23–5.20 (m, 1H), 5.32–5.29 (m, 1H), 4.39–4.36 (m, 1H), 2.47–2.42 (m, 2H), 2.23–2.17 (m, 1H), 2.03–1.95 (m, 1H), 1.44 (s, 9H).

4.9.2. *tert*-Butyl (S)-4-(((allyloxy)carbonyl)amino)-5-(methoxy-(methyl)amino)-5-oxopentanoate

To a cooled solution of (S)-2-(((allyloxy)carbonyl)amino)-5-(*tert*-butoxy)-5-oxopentanoic acid (19.7 g, 68.5 mmol) in DCM (390 mL) were added *N,O*-dimethylhydroxylamine hydrochloride (8.02 g, 82.2 mmol), 4-methylmorpholine (9.04 mL, 82.2 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (15.7 g, 82.2 mmol). After 3 h of stirring at room temperature, the medium was washed with aqueous HCl (1 N), with brine, dried over sodium sulphate, filtered and concentrated in vacuo. Purification of the residue by chromatography on silica gel (cyclohexane-EtOAc, gradient of 9/1 to 6/4) afforded the title compound (16.5 g, 72%, as colorless oil): ^1H NMR (CDCl_3 , 500 MHz) δ 5.86–5.93 (m, 1H), 5.48 (br d, $J = 8.5$ Hz, 1H), 5.31–5.27 (m, 1H), 5.21–5.18 (m, 1H), 4.75–4.70 (m, 1H), 4.57–4.50 (m, 2H), 3.77 (s, 3H), 3.20 (s, 3H), 2.31 (t, $J = 7.5$ Hz, 2H), 2.06–2.00 (m, 1H), 1.89–1.84 (m, 1H), 1.42 (s, 9H).

4.9.3. *tert*-Butyl (S)-4-(((allyloxy)carbonyl)amino)-5-oxopentanoate

A solution of lithium aluminium hydride (2 N in THF, 4.92 mL, 9.8 mmol) was added dropwise to a cooled (-78°C) solution of *tert*-butyl (S)-4-(((allyloxy)carbonyl)amino)-5-(methoxy-(methyl)amino)-5-oxopentanoate (5.0 g, 15.1 mmol) in anhydrous THF (67 mL). The mixture was stirred at -78°C for 3 h 30, then aqueous HCl (1 N) was slowly added to the medium, and the temperature was allowed to warm to 0°C . The mixture was diluted with EtOAc. The aqueous layer was extracted (EtOAc, two times). The combined organic layer was washed with aqueous HCl (1 N), with brine, dried over sodium sulphate, filtered and concentrated in vacuo to afford the title compound (4.27 g, quantitative, as yellow oil): ^1H NMR (CDCl_3 , 500 MHz): δ 9.59 (s, 1H), 5.95–5.87 (m, 1H), 5.50 (br s, 1H), 5.31 (d, $J = 17$ Hz, 1H), 5.23–5.21 (m, 1H), 4.58 (d, $J = 5.5$ Hz, 2H), 4.31–4.28 (m, 1H), 2.40–2.26 (m, 2H), 2.25–2.21 (m, 1H), 1.93–1.86 (m, 1H), 1.42 (s, 9H).

4.9.4. *tert*-Butyl (S)-4-(((allyloxy)carbonyl)amino)-5,5-diethoxypentanoate

To a freshly prepared solution of *tert*-butyl (S)-4-(((allyloxy)carbonyl)amino)-5-oxopentanoate (4.27 g, 15.7 mmol) in absolute ethanol (25 mL) were added, under Argon atmosphere, triethyl orthoformate (15.7 mL, 94.4 mmol), *p*-toluenesulfonic acid (81 mg, 0.47 mmol) and 3 Å molecular sieves. After stirring at room temperature overnight, the mixture was filtered over a pad of Celite and rinsed with EtOH. The filtrate was concentrated under reduced pressure and co-evaporated with toluene (three times). Purification of the residue by flash chromatography on silica gel (cyclohexane-EtOAc, gradient 9/1 to 8/2) afforded the title compound (4.40 g, 81%, as pale yellow oil): LCMS ($t_R = 3.63$ min, purity = 98%), $\text{ESI}^+ m/z$ 300.1 ($\text{M}-\text{OEt}+\text{H}^+$); ^1H NMR (500 MHz, CDCl_3) δ 5.95–5.83 (m, 1H), 5.30 (dq, $J = 17.2$ Hz and 1.6 Hz, 1H), 5.19 (dq, $J = 10.4$ Hz and 1.4 Hz, 1H), 4.90 (d, $J = 9.5$ Hz, 1H), 4.55 (m, 2H), 4.36 (d, $J = 2.8$ Hz, 1H), 3.80–3.74 (m, 1H), 3.73–3.66 (m, 2H), 3.55–3.48 (m, 2H), 2.30 (t, $J = 7.5$ Hz, 2H), 1.96–1.88 (m, 1H), 1.73–1.68 (m, 1H), 1.43 (s, 9H), 1.21 (m, 6H); ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 172.03, 155.88, 133.85, 116.59, 103.03, 79.41, 64.17, 62.79, 61.79, 52.19, 31.42, 27.75, 24.36,

15.26; $[\alpha]_D^{20} = -25.5^\circ$ ($c = 10$ g/L, EtOH); HRMS ($\text{M}+\text{H}^+$) calculated for $\text{C}_{17}\text{H}_{31}\text{NO}_6$ 345.2151; found 368.2083 ($\text{M}+\text{Na}^+$), 713.4276 ($2\text{M}+\text{Na}^+$), 244.1206 cyclized warhead eg., ($\text{M}(-\text{OEt}, -\text{C}_4\text{H}_9)+\text{H}^+$).

4.9.5. *tert*-Butyl (4S)-5,5-diethoxy-4-(2-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)-benzamido)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)propanamido)pentanoate

Step 1: To a stirred solution 2-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)benzamido)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)propanoic acid (130 mg, 0.26 mmol, 1.00 eq.) and pentafluorophenol (52.6 mg, 0.29 mmol, 1.10 eq.) in a mixture of DCM (2.6 mL) and DMF (1.3 mL), was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (54.8 mg, 0.29 mmol, 1.10 eq.) and the reaction mixture was stirred at room temperature for 30 min.

Step 2: In a separate flask, a solution of (*R*)-3-allyloxycarbonylamino-5,5-diethoxy-pentanoic acid *tert*-butyl ester (135 mg, 0.39 mmol, 1.50 eq.) and 1,3-dimethylbarbituric acid (64.9 mg, 0.42 mmol, 1.60 eq.) in a mixture of DCM (2.6 mL) and DMF (650 μL) was degassed and purged with nitrogen then tetrakis(triphenylphosphine)palladium(0) (12.0 mg, 0.01 mmol, 0.04 eq.) was added. The reaction mixture was stirred at r.t. for 30 min.

Step 3: The solution from the Alloc deprotection containing *tert*-butyl (*R*)-3-amino-5,5-diethoxypentanoate was added dropwise to the activated ester formed in Step 1 and the resulting solution was stirred for 2 h at r.t. The reaction mixture was diluted with DCM (30 mL) and washed with a saturated aqueous solution of NaHCO_3 . The aqueous phase was washed with DCM (2×10 mL). The organic phases were combined, dried over MgSO_4 and concentrated to dryness. The residue was purified by flash chromatography (silica gel, gradient of 0–50% EtOAc in heptane) to afford *tert*-butyl (4S)-5,5-diethoxy-4-(2-(3-isopropyl-5-(2-methyl-4-(naphthalen-2-ylamino)-benzamido)-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)propanamido)pentanoate (160 mg, 83%) as a beige solid: LCMS ($t_R = 1.44$ min, purity = 100%), $\text{ESI}^+ m/z$ 744.46 ($\text{M}+\text{H}^+$); ^1H NMR ($\text{DMSO}-d_6$) δ 8.94 (d, $J = 17.4$ Hz, 1H), 8.77 (d, $J = 4.5$ Hz, 1H), 7.77–7.94 (m, 3H), 7.58–7.65 (m, 2H), 7.55 (dd, $J = 8.5$, 1.8 Hz, 1H), 7.48 (t, $J = 7.5$ Hz, 1H), 7.38 (ddd, $J = 10.4$, 7.3, 4.5 Hz, 2H), 7.03–7.16 (m, 2H), 5.29 (qd, $J = 6.9$, 4.4 Hz, 1H), 4.55 (ddd, $J = 13.4$, 7.9, 3.4 Hz, 1H), 3.40–3.71 (m, 4H), 2.50 (d, $J = 1.9$ Hz, 3H), 2.26–2.40 (m, 2H), 1.57–1.86 (m, 2H), 1.49 (dd, $J = 17.7$, 5.9 Hz, 3H), 1.35–1.44 (s, 9H), 1.41 (m, 6H), 1.06–1.22 (m, 6H).

4.9.6. *N*-(3-(1-(((3S)-2-Hydroxy-6-oxotetrahydro-2H-pyran-3-yl)amino)-1-oxopropan-2-yl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)benzamide (39)

To a stirred solution of (S)-5,5-diethoxy-4-(2-(3-isopropyl-5-[2-methyl-4-(naphthalen-2-ylamino)-benzoylamino]-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl)-propionylamino)-pentanoic acid *tert*-butyl ester (105 mg, 0.14 mmol, 1.00 eq.) in DCM (3.15 mL) was added trifluoroacetic acid (3.15 mL, 41.1 mmol) at 0°C and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was treated with a saturated aqueous solution of NaHCO_3 (aq) to bring the pH to 5 and extracted with DCM (2×5 mL). The organic phases were combined, dried over MgSO_4 and concentrated to dryness. The crude product was purified by flash chromatography (silica gel, gradient of 0–10% MeOH in DCM). After concentration of the fractions to dryness, the gum was triturated in EtOAc and the solid was collected and dried in a vacuum oven at 40°C to afford *N*-(3-(1-(((3S)-2-hydroxy-6-oxotetrahydro-2H-pyran-3-yl)amino)-1-oxopropan-2-yl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-methyl-4-(naphthalen-2-ylamino)benzamide (32.0 mg, 35%) as a pale pink solid: LCMS ($t_R = 5.57$ min, purity = 93%), $\text{ESI}^+ m/z$ 612.35 ($\text{M}+\text{H}^+$); ^1H NMR

(DMSO- d_6) δ 12.18 (s, 1H), 9.40 (d, J = 17.4 Hz, 1H), 8.94 (d, J = 5.6 Hz, 1H), 8.72 (s, 1H), 8.42 (s, 1H), 7.72–7.88 (m, 3H), 7.58 (d, J = 2.2 Hz, 1H), 7.50 (d, J = 8.5 Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 7.27–7.38 (m, 2H), 7.05 (dd, J = 18.0, 5.4 Hz, 2H), 5.40 (p, J = 6.8 Hz, 1H), 4.78 (td, J = 6.8, 3.2 Hz, 1H), 2.44 (s, 3H), 2.15–2.33 (m, 2H), 1.96–2.02 (m, 1H), 1.77–1.60 (m, 1H), 1.45 (d, J = 6.9 Hz, 3H), 1.33 (q, J = 7.4, 6.4 Hz, 6H); ^{13}C NMR (101 MHz, DMSO- d_6) δ 169.60, 167.47, 159.04, 156.32, 149.35, 145.38, 145.04, 140.15, 134.26, 131.60, 129.56, 128.99, 128.72, 127.50, 126.52, 126.40, 123.46, 120.60, 118.21, 113.60, 111.53, 112.81, 100.54, 95.21, 58.72, 58.29, 58.04, 20.93, 20.69, 20.57, 13.95, 13.87; HRMS: (M+H) $^+$ calculated for $\text{C}_{33}\text{H}_{35}\text{N}_5\text{O}_7$ 614.2536; found 614.2603.

Acknowledgments

The authors would like to acknowledge the support of our CRO partners, Spirochem, Santai Labs and Syngene.

References

- [1] D.R. McIlwain, T. Berger, T.W. Mak, *Cold Spring Harb. Perspect. Biol.* (2013) 1–28.
- [2] a) S.M. Tachay, E. Makrantonaki, R. Ganceviciene, C. Dessinioti, S.R. Feldman, C.C. Zouboulis, *Nat. Rev. Disease Primers* 1 (2015) 1–20;
b) C. Dessinioti, A. Katsambas, *Clin. Dermatol.* 28 (2010) 2–7.
- [3] a) M. Kistowska, S. Gehrke, D. Jankovic, K. Kerl, A. Fettelschoss, L. Feldmeyer, G. Fenini, A. Kolios, A. Navarini, R. Ganceviciene, J. Schaubert, E. Contassot, L.E. French, *J. Invest. Dermatol.* 134 (2014) 677–685;
b) E. Contassot, L.E. French, *J. Invest. Dermatol.* 134 (2014) 310–313.
- [4] H.-L. Kelh, R. Palatsi, N. Fyhrquist, S. Lehtimki, J.P. Vrynen, M. Kallioinen, M.E. Kubin, D. Greco, K. Tasanen, H. Alenius, B. Bertino, I. Carlvn, B. Mehul, S. Dret, P. Reiniche, P. Martel, C. Marty, U. Blume-Peytavi, J.J. Voegel, A. Lauerma, *PLoS One* 9 (2014) 1–18.
- [5] a) T. O'Brien, S.D. Linton, *Design of Caspase Inhibitors as Potential Clinical Agents*, CRC Press/Taylor & Francis Group, Boca Raton, 2009, pp. 82–132;
b) M. Poreba, A. Strozzyk, G.S. Salvesen, M. Drag, *Cold Spring Harb. Perspect. Biol.* (2013) 1–20;
c) N.A. Thornberry, H.G. Bull, J.R. Calaycay, K.T. Chapman, A.D. Howard, M.J. Kostura, D.K. Miller, S.M. Molineaux, J.R. Weidner, J. Aunins, K.O. Elliston, J.M. Ayala, F.J. Casano, J. Chin, G.J.-F. Ding, L.A. Egger, E.P. Gaffney, G. Limjoco, O.C. Palyha, S.M. Raju, A.M. Rolando, J.P. Salley, T.-T. Yamin, T.D. Lee, J.E. Shively, M. MacCross, R.A. Mumford, J.A. Schmidt, M.J. Tocci, *Nature* 356 (1992) 768–774.
- [6] a) B. Howley, H.O. Fearnhead, *J. Cell Mol. Med.* 12 (2008) 1502–1516;
b) S.H. MacKenzie, J.L. Schipper, A.C. Clark, *Curr. Opin. Drug Discov. Dev* 13 (2010) 568–576;
c) W. Wannamaker, R. Davies, M. Namchuk, J. Pollard, P. Ford, G. Ku, C. Decker, P. Charifson, P. Weber, U.A. Germann, K. Kuida, J.C. Randle, *J. Pharmacol. Exp. Therapeut.* 321 (2007) 509–516.
- [7] J.-F. Fournier, L. Clary, S. Chambon, L. Dumais, C.S. Harris, C. Millois, R. Pierre, S. Talano, E. Thoreau, J. Aubert, M. Aurelly, C. Bouix-Peter, A. Brethon, L. Chantalat, O. Christin, G. El-Bazbouz, A.-L. Ghilin, T. Isabet, C. Lardy, A.-P. Luzy, C. Mathieu, K. Mebrouk, D. Orifla, J. Pascau, K. Reverse, R. Roche, V. Rodeschini, L.F. Hennequin, *J. Med. Chem.* 61 (2018) 4030–4051.
- [8] A. Brethon, C. Bouix-Peter, L. Clary, J.-F. Fournier, C.S. Harris, C. Lardy, D. Roche, V. Rodeschini, S. Talano, *Tetrahedron Lett.* 57 (2016) 5924–5927.
- [9] L. Trottet, H. Maibach, *Dermal Drug Selection and Development - an Industrial Perspective*, Springer, 2017, pp. 29–48.
- [10] a) R.-K. Chang, A. Raw, R. Lionberger, L. Yu, C.J. Muggleston, *AAPS J.* 15 (2013) 41–52;
b) S. Mariz, M.E. Lanec, *Int. J. Pharm.* 435 (2012) 22–26.
- [11] J.-G. Boiteau, C. Bouix-Peter, S. Chambon, L. Clary, S. Daver, L. Dumais, J.-F. Fournier, C.S. Harris, K. Mebrouk, C. Millois, R. Pierre, N. Rodeville, S. Talano, L. Tomas, *Tetrahedron Lett.* 57 (2016) 2367–2371.
- [12] T. O'Brien, B.T. Fahr, M.M. Sopko, J.W. Lam, N.D. Waal, B.C. Raimundo, H.E. Purkey, P. Pham, M.J. Romanowski, *Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.* 61 (2005) 451–458.
- [13] T.T. Talele, *J. Med. Chem.* 59 (2016) 8712–8756.
- [14] K. Ramadas, N. Srinivasan, *Synth. Commun.* 22 (1992) 3189–3195.
- [15] A. El-Faham, R. Subirs-Funosas, R. Prohens, F. Albericio, *Chem. Eur. J.* 15 (2009) 9404–9416.
- [16] Data supporting the chiral degradation study looking notably at the effect of changing excipients, temperature and pH is included in the supporting information.
- [17] Wos, J. A.; Wang, Y.; Oppong, K. A.; O'Neill, S. V.; Laufersweiler, M. C.; Soper, D. L.; De, B.; Demuth, T. P. WO 2003103677.